U.S. patent number 9,139,517 [Application Number 14/076,406] was granted by the patent office on 2015-09-22 for anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use.
This patent grant is currently assigned to XenoPort, Inc.. The grantee listed for this patent is XenoPort, Inc.. Invention is credited to Sudhir Joshi, Suresh K. Manthati, Stephen P. Raillard.
United States Patent |
9,139,517 |
Raillard , et al. |
September 22, 2015 |
Anhydrous and hemihydrate crystalline forms of an (R)-baclofen
prodrug, methods of synthesis and methods of use
Abstract
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical
compositions comprising such compounds, methods of making and
methods of using the same are disclosed.
Inventors: |
Raillard; Stephen P. (Mountain
View, CA), Manthati; Suresh K. (Sunnyvale, CA), Joshi;
Sudhir (Visp, CH) |
Applicant: |
Name |
City |
State |
Country |
Type |
XenoPort, Inc. |
Santa Clara |
CA |
US |
|
|
Assignee: |
XenoPort, Inc. (Santa Clara,
CA)
|
Family
ID: |
46690752 |
Appl.
No.: |
14/076,406 |
Filed: |
November 11, 2013 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20140066501 A1 |
Mar 6, 2014 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
13572367 |
Aug 10, 2012 |
8580850 |
|
|
|
61508286 |
Aug 11, 2011 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K
31/325 (20130101); A61P 25/30 (20180101); A61P
11/00 (20180101); A61P 1/04 (20180101); C07C
271/22 (20130101); A61P 19/00 (20180101); A61P
29/00 (20180101); C07B 2200/13 (20130101); C07B
2200/07 (20130101) |
Current International
Class: |
C07C
271/22 (20060101) |
Field of
Search: |
;514/487 ;560/30 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
1178034 |
|
Feb 2002 |
|
EP |
|
91/08740 |
|
Jun 1991 |
|
WO |
|
01/08675 |
|
Feb 2001 |
|
WO |
|
01/26638 |
|
Apr 2001 |
|
WO |
|
01/90052 |
|
Nov 2001 |
|
WO |
|
02/096404 |
|
Dec 2002 |
|
WO |
|
2005/019163 |
|
Mar 2005 |
|
WO |
|
2008/086492 |
|
Jul 2008 |
|
WO |
|
WO 2008/086492 |
|
Jul 2008 |
|
WO |
|
2009/096985 |
|
Aug 2009 |
|
WO |
|
WO 2009/096985 |
|
Aug 2009 |
|
WO |
|
Other References
Caira, "Crystalline Polymorphism of Organic Compounds," Topics in
Current Chemistry, vol. 198, 1998, pp. 163-208. cited by applicant
.
Lal et al., "Arbaclofen Placarbil, A Novel R-Baclofen Prodrug:
Improved Absorption, Distribution, Metabolism, and Elimination
Properties Compared with R-Baclofen," The Journal of Pharmacology
and Experimental Therapeutics, The American Society for
Pharmacology and Experimental Therapeutics, vol. 330, No. 3, Sep.
1, 2009, pp. 911-921. cited by applicant .
Addolorato et al., "Baclofen efficacy in reducing alcohol craving
and intake: a preliminary double-blind randomized controlled
study," Alcohol & Alcoholism (2002) 37(5):504-508. cited by
applicant .
Ahmadi-Abhari et al., "Baclofen versus clonidine in the treatment
of opiates withdrawal, side-effects aspect: a double-blind
randomized controlled trial," J Clin Pharm Ther. (2001) 26:67-71.
cited by applicant .
Aley et al., "Vincristine hyperalgesia in the rat: a model of
painful vincristine neuropathy in humans," Neurosci. (1996), 73(1):
259-265. cited by applicant .
Anghinah et al., "Effect of baclofen on pain in diabetic
neuropathy," Muscle & Nerve (1994) 17(8):958-9. cited by
applicant .
Argoff, "Pharmacologic management of chronic pain," JAOA Supp. 3
(2002), 102(9): S21-S26. cited by applicant .
Assadi et al., "Baclofen for maintenance treatment of opioid
dependence: a randomized double-blind placebo-controlled clinical
trial," BMC Psychiatry (2003), 3(16) (10 pages). cited by applicant
.
Authier et al., "Assessment of allodynia and hyperalgesia after
cisplatin administration to rats," Neurosci. Lett. (2000), 291:
73-76. cited by applicant .
Backonja et al., "Gabapentin dosing for neuropathic pain: evidence
from randomaized, placebo-controlled clinical trials," Clin. Ther.
(2003), 25: 81-104. cited by applicant .
Balerio et al., "Baclofen analgesia: involvement of the GABAergic
system," Pharm. Res. (2002) 46(3):281-286. cited by applicant .
Baron, "Mechanisms of disease: neuropathic pain--a clinical
perspective," Nat. Clin. Pract. Neurol. (2006), 2(2): 95-106. cited
by applicant .
Becker et al., "Intrathecal baclofen alleviates autonomic
dysfunction in severe brain injury," J Clin. Neurosci. (2000)
7(4):316-319. cited by applicant .
Beggs et al., "Neuropathic pain: symptoms, models and mechanisms,"
Drug Dev. Res. (2006), 67: 289-301. cited by applicant .
Bennett et al., "A peripheral mononeuropathy in rat that produces
disorders of pain sensation like those seen in man," Pain (1988),
33: 87-107. cited by applicant .
Blackshaw et al., "Inhibition of transient LES relaxations and
reflux in ferrets by GABA receptor agonists," Am. J. Physiol.
(1999), 277: G867-G874. cited by applicant .
Bowery, "GABA.sub.B receptors and their significance in mammalian
pharmacology," Trends Pharmacol. Sci. (1989) 10:401-407. cited by
applicant .
Brebner et al., "A potential role for GABA.sub.B agonists in the
treatment of psychostimulant addiction," Alcohol & Alcoholism
(2002) 37(5):478-484. cited by applicant .
Caira, "Crystalline Polymorphism of Organic Compounds," Topics in
Current Chemistry (1998) 198, pp. 163-208. cited by applicant .
Castell et al., "XP19986 decreases reflux and is well tolerated in
GERD patients," Am J. Gastroenterology (2006) 101(suppl 2)(52), S59
and poster presentation at American College of Gastroenterology
2006 Annual Meeting, Oct. 20-25, 2006, Las Vegas, NV. cited by
applicant .
Castell et al., "R-baclofen prodrug XP19986 decreases reflux
episodes and is well tolerated in GERD patients," Gastroenterology
(2007) suppl. A, 486 and poster presentation at Digestive Disease
Week Meeting, May 19-24, 2007, Washington D.C. cited by applicant
.
Cavaletti et al., "Experimental peripheral neuropathy induced in
adult rats by repeated intraperitoneal administration of Taxol,"
Exp. Neurol. (1995), 133: 64-72. cited by applicant .
Chacur et al., "A new model of sciatic inflammatory neuritis (SIN):
induction of unilateral and bilateral mechanical allodynia
following acute unilateral peri-sciatic immune activation in rats,"
Pain (2001), 94: 231-244. cited by applicant .
Chai et al., "Influence of aminooxyacetic acid, a y-aminobutyrate
transaminase inhibitor, on hereditary spastic defect in the mouse,"
Proc. Soc. Exptl. Biol. Med. (1962), 109: 491-495. cited by
applicant .
Chan et al., "Action of anti-tussive drugs on the emetic reflex of
Suncus murinus (house musk shrew)," Eur. J. Pharmacol. (2007)
559:196-201. cited by applicant .
Chaplan et al., "Quantitative assessment of tactile allodynia in
the rat paw," J. Neurosci. Meth. (1994), 53: 55-63. cited by
applicant .
Ciccaglione et al., "Effect of acute and chronic administration of
the GABA.sub.B agonist baclofen on 24 hour pH metry and symptoms in
control subjects and in patients with gastro-oesophageal reflux
disease," Gut (2003) 52:464-470. cited by applicant .
Cousins et al., "GABA.sub.Breceptor agonists for the treatment of
drug addiction: a review of recent findings," Drug and Alcohol
Depend. (2002) 65:209-220. cited by applicant .
Crofford et al., "Pregabalin for the treatment of fibromyalgia
syndrome," Arth. Rheum. (2005), 52(4): 1264-1273. cited by
applicant .
Dapas et al., "Baclofen for the treatment of acute low-back
syndrome--a double-blind comparison with placebo," Spine (1985)
10(4):345-349. cited by applicant .
De Leo et al., "Characterization of a neuropathic pain model:
sciatic cryoneurolysis in the rat," Pain (1994), 56: 9-16. cited by
applicant .
De Vry et al., "Pharmacological characterization of the chronic
pain construction injury model of neuropathic pain," Eur. J.
Pharmacol. (2004), 491: 137-148. cited by applicant .
Decosterd et al., "Spared nerve injury: an animal model of
persistent peripheral neuropathic pain," Pain (2000), 87: 149-158.
cited by applicant .
Dicpinigaitis et al., "Antitussive effect of the GABA-agonist
baclofen," Chest (1997) 111:996-999. cited by applicant .
Dicpinigaitis et al., "Inhibition of capsaicin-induced cough by the
y-aminobutyric acid agonist baclofen," J Clin Pharmacol (1998)
38:364-367. cited by applicant .
Dirig et al., "Intrathecal baclofen and muscimol, but not
midazolam, are antinociceptive using the rat-formalin model," JPET
(1995), 275(1): 219-227. cited by applicant .
Dunham et al., "A note on a simple apparatus for detecting
neurological deficit in rats and mice," J. Am. Pharm. Assoc.
(1957), 46(3): 208-09. cited by applicant .
Eaton, "Common animal models for spasticity and pain," J. Rehab.
Res. Dev. (2003), 40(4): 41S-54S. cited by applicant .
Endo et al., "The ferret: a cytotoxic drug-induced emesis model,"
Biogenic Amines (2004), 18(3-6): 419-434. cited by applicant .
Fattore et al., "Baclofen antagonizes intravenous
self-administration of nicotine in mice and rats," Alcohol &
Alcoholism (2002), 37(5): 495-498. cited by applicant .
Flannery et al., "Baclofen for alcohol dependence: a preliminary
open-label study," Alcohol Clin. Exp. Res. (2004) 28(10):1517-1523.
cited by applicant .
Fox et al., "Critical evaluation of the streptozotocin model of
painful diabetic neuropathy in the rat," Pain (1999), 81: 307-316.
cited by applicant .
Fox et al., "Comparative activity of the anti-convulsants
oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model
of neuropathic pain in the rat and guinea-pig," Pain (2003), 105:
355-362. cited by applicant .
Freitag, "Preventative treatment for migraine and tension-type
headaches: do drugs having effects on muscle spasm and tone have a
role?," CNS Drugs (2003) 17(6), 373-381. cited by applicant .
Freynhagen et al., "Efficacy of pregabalin in neuropathic pain
evaluated in a 12-week, randomised, double-blind, milticentre,
placebo-controlled trial of flexible- and fixed-dose regimens,"
Pain (2005), 115: 254-263. cited by applicant .
Fromm et al., "Baclofen in the treatment of trigeminal neuralgia:
double-blind study and long-term follow-up," Ann. Neurol. (1984)
15:240-244. cited by applicant .
Fromm et al., "Role of inhibitory mechanisms in trigeminal
neuralgia," Neurology (1981) 31:683-687. cited by applicant .
Gatscher et al., "Combined intrathecal baclofen and morphine
infusion for the treatment of spasticity related pain and central
deafferentiation pain," Acta Neurochir (2001) 79(Suppl):75-76.
cited by applicant .
Gidal et al., "New and emerging treatment options for neuropathic
pain," Am. J. Manag. Care (2006), 12: S269-S278. cited by applicant
.
Gruenthal et al., "Gabapentin for the treatment of spasticity in
patients with spinal cord injury," Spinal Cord (1997), 35: 686-689.
cited by applicant .
Guay, "Pregabalin in neuropathic pain: a more "pharmaceutically
elegant" gabapentin?," Am. J. Geriat.r Pharmacother. (2005), 3(4):
274-287. cited by applicant .
Haney et al., "Effects of baclofen on cocaine self-administration:
opioid- and nonopioid-dependent volunteers,"
Neuropsychopharmacology (2006) 31:181-421. cited by applicant .
Hao et al., "Allodynia-like effects in rat after ischaemic spinal
cord injury photochemically induced by laser irradiation," Pain
(1991), 45: 175-185. cited by applicant .
Hefferan et al., "Development of baclofen tolerance in a rat model
of chronic spasticity and rigidity," Neurosci. Lett. (2006), 403:
195-200. cited by applicant .
Heinzerling et al., "Randomized, placebo-controlled trial of
baclofen and gabapentin for the treatment of methamphetamine
dependence," Drug Alcohol Depend. (2006) 85:177-184. cited by
applicant .
Hering-Hanit et al., "Baclofen in cluster headache," Headache
(2000) 40:48-51. cited by applicant .
Hering-Hanit, "Baclofen for prevention of migraine," Cephalalgia
(1999) 19:589-591. cited by applicant .
Herman et al., "Intrathecal baclofen suppresses central pain in
patients with spinal lesions," A pilot study, Clin J Pain (1992)
8:338-345. cited by applicant .
Herzberg et al., "Peripheral nerve exposure to HIV viral envelope
protein gp120 induces neuropathic pain and spinal gliosis," J.
Neuroimmunol. (2001), 116: 29-39. cited by applicant .
Hornby et al., "Central mechanisms of lower esophageal sphincter
control," Gastroenterol. Clin. N. Am. (2002) 31(4 Suppl):S11-S20.
cited by applicant .
Hwang et al., "The effect of spinal GABA receptor agonists on
tactile allodynia in a surgically-induced neuropathic pain model in
the rat," Pain (1997) 70:15-22. cited by applicant .
Irwin, "Comprehensive observational assessment: la. A systematic,
quantitative procedure for assessing the behavioral and physiologic
state of the mouse," Psychopharmacologia (1968), 13: 222-257. cited
by applicant .
Jensen et al., "The clinical picture of neuropathic pain," Eur. J.
Pharmacol. (2001), 429: 1-11. cited by applicant .
Joseph et al., "Novel mechanism of enhanced nociception in a model
of AIDS therapy-induced painful neuropathy in the rat," Pain
(2004), 107: 147-158. cited by applicant .
Kakinohana et al., "Development of GABA-sensitive spasticity and
rigidity in rats after transient spinal cord ischemia: a
qualitative and quantitative electrophysiological and
histopathological study," Neurosci. (2006), 141: 15691583. cited by
applicant .
Katz, "Management of spasticity," Am. J. Phys. Med. Rehab. (1988)
67(3), 108-16. cited by applicant .
Kehl et al., "A new animal model for assessing mechanisms and
management of muscle hyperalgesia," Pain (2000), 85: 333-343. cited
by applicant .
Kim and Chung, "An experimental model for peripheral neuropathy
produced by segmental spinal nerve ligation in the rat," Pain
(1992), 50: 355-363. cited by applicant .
Krach, "Pharmacotherapy of spasticity: oral medications and
intrathecal baclofen," J. Child Neurol. (2001) 16:31-36. cited by
applicant .
Kupers et al.,"Photochemically-induced ischemia of the rat sciatic
nerve produces a dose-dependent and highly reproducible mechanical,
heat and cold allodynia, and signs of spontaneous pain," Pain
(1998), 76: 45-59. cited by applicant .
Lal et al., "Arbaclofen placarbil, a novel R-baclofen prodrug:
improved absorption, distribution, metabolism, and elimination
properties compared with R-baclofen," J Pharmacology Experimental
Therapeutics (2009) 330:911-921. cited by applicant .
Lehmann et al., "Activation of the GABA.sub.B receptor inhibits
transient lower esophageal sphincter relaxation in dogs,"
Gastroenterology (1999), 117: 11471154. cited by applicant .
Lewis et al., "Animal models of cough: literature review and
presentation of a novel cigarette smoke-enhanced cough model in the
guinea-pig," Pulm. Pharm. Ther. (2007), 20: 325-333. cited by
applicant .
Li et al., "Effects of baclofen on spinal reflexes and persistent
inward currents in motoneurons of chronic spinal rats with
spasticity," J. Neurophysiol. (2004), 92: 2694-2703. cited by
applicant .
Lidums et al., "Control of transient lower esophageal sphincter
relaxations and reflux by the GABA.sub.B agonist baclofen in normal
subjects," Gastroenterology (2000) 118:7-13. cited by applicant
.
Ligresti et al., "New potent and selective inhibitors of anandamide
reuptake with antispastic activity in a mouse model of multiple
sclerosis," Br. J. Pharm. (2006), 147: 83-91. cited by applicant
.
Liu et al., "Pica--a model of nausea? Species differences in
response to cisplatin," Physiol. Behav. (2005), 85: 271-277. cited
by applicant .
Lombard et al., "Deafferentiation hypersensitivity in the rat after
dorsal rhizotomy: a possible animal model of chronic pain," Pain
(1979), 6: 163-174. cited by applicant .
Loscher and Schmidt, "Which animal models should be used in the
search for now antiepileptic drugs? A proposal based on
experimental and clinical considerations," Epilepsy Res. (1988), 2:
145-181. cited by applicant .
Maccioni et al., "Baclofen-induced reduction of alcohol
reinforcement in alcohol-preferring rats," Alcohol (2005), 36:
161-168. cited by applicant .
Malik et al., "Differential effects of dexamethasone, ondansetron
and tachykinin NK.sub.1 receptor agonist (GR205171) on
cisplatin-induced changes in behaviour, food intake, pica and
gastric function in rats," Eur. J. Pharmacol. (2007), 555: 164-173.
cited by applicant .
Markou et al., "Role of y-aminobutyric acid (GABA) and metabotropic
glutamate receptors in nicotine reinforcement: potential
pharmacotherapies for smoking cessation," Ann N.Y. Acad. Sci.
(2004) 1025:491-503. cited by applicant .
Meleger et al., "Neck and back pain: musculoskeletal disorders,"
Neurol. Clin. (2007) 25:419-438. cited by applicant .
Milligan et al., "Thermal hyperalgesia and mechanical allodynia
produced by intrathecal administration of the human
immunodeficiency virus-1 (HIV-1) envelope glycoprotein gp120,"
Brain Res. (2000), 861: 105-116. cited by applicant .
Misgeld et aL, "A physiological role for GABA.sub.B receptors and
the effects of baclofen in the mammalian central nervous system,"
Prog. Neurobiol. (1995) 46:423-462. cited by applicant .
Mosconi and Kruger, "Fixed diameter polyethylene cuffs applied to
the rat sciatic nerve induce a painful neuropathy: ultrastructural
morphometric analysis of axonal alterations," Pain (1996), 64:
37-57. cited by applicant .
Patel et al., "The effects of GABA.sub.B agonists and gabapentin on
mechanical hyperalgesia in models of neuropathic and inflammatory
pain in the rat," Pain (2001) 90(3):217-26. cited by applicant
.
Polomano et al., "A painful peripheral neuropathy in the rat
produced by the chemotherapeutic drug, paclitaxel," Pain (2001),
94: 293-304. cited by applicant .
Priebe et al., "Effectiveness of gabapentin on controlling
spasticity: a quantitative study," Spinal Cord (1997), 35: 171-175.
cited by applicant .
Raphael et al., "Long-term experience with implanted intrathecal
drug administration systems for failed back syndrome and chronic
mechanical low back pain," BMC Musculoskeletal Disorders (2002)
3(17): 1-8. cited by applicant .
Reis et al., "Baclofen, an agonist at peripheral GABA.sub.B
receptors, induces antinociception via activation of TEA-sensitive
potassium channels," Br J Pharmacol (2006) 149(6):733-739. cited by
applicant .
Rhodes et al., "Nausea, vomiting, and retching: complex problems in
palliative care," CA Cancer J. Clin. (2001), 51: 232-248. cited by
applicant .
Ringel et al., "Glossopharyngeal neuralgia: successful treatment
with baclofen," Ann Neurol (1987) 21(5):514-515. cited by applicant
.
Sanger et al., "Classification and definition of disorders causing
hypertonia in childhood," Pediatrics (2003), 111: e89-e97. cited by
applicant .
Seltzer et al., "A novel behavioral model of neuropathic pain
disorders produced in rats by partial sciatic nerve injury," Pain
(1990), 43: 205-218. cited by applicant .
Shimizu et al., "GABA.sub.B receptors do not mediate inhibitory
actions of gabapentin on the spinal reflux in rats," J. Pharmacol.
Sci. (2004), 96: 444-449. cited by applicant .
Sindrup and Jensen, "Efficacy of pharmacological treatments of
neuropathic pain: an update and effect related to mechanism of drug
action," Pain (1999), 83: 389-400. cited by applicant .
Slart et al., "An animal model of pain produced by systemic
administration of an immumotherapeutic anti-ganglioside antibody,"
Pain (1997), 69: 119-125. cited by applicant .
Slonimski et al., "Intrathecal baclofen in pain management," Reg
Anesth Pain Med (2004) 29(3):269-276. cited by applicant .
Smith et al., "Increased sensitivity to the antinociceptive
activity of (+/-)-baclofen in an animal model of chronic
neuropathic, but not chronic inflammatory hyperalgesia,"
Neuropharmacology (1994) 33(9):1103-1108. cited by applicant .
Spano et al., "The GABA.sub.B receptor agonist baclofen prevents
heroin-induced reinstatement of heroin-seeking behavior in rats,"
Neuropharmacol. (2007), 52: 1555-1562. cited by applicant .
Stakeberg and Lehmann, "Influence of different intragastric stimuli
on triggering of transient lower oesophageal sphincter relaxation
in the dog," Neurogastroenterol. Mot. (1999), 11: 125-132. cited by
applicant .
Steeves et al., "Guidelines for the conduct of clinical trials for
spinal cord injury (SCI) as developed by the ICCP panel: clinical
trial outcome measures," Spinal Cord (2007), 45: 206-221. cited by
applicant .
Suzuki et al., "Effect of a selective GABA.sub.B receptor agonist
baclofen on the .mu.-opioid receptor agonist-induced
antinociceptive, emetic and rewarding effects," Neuropharmacology
(2005) 49:1121-1131. cited by applicant .
Taylor-Gjevre et al., "Anti-glutamic acid decarboxylase antibodies
in a patient with systemic lupus erythematosus and fibromyalgia
symptoms," Lupus (2005) 14:486-488. cited by applicant .
Tuszynski et al., "Guidelines for the conduct of clinical trials
for spinal cord injury as developed by the ICCP panel: clinical
trial inclusion/exclusion criteria and ethics," Spinal Cord (2007),
45: 222-231. cited by applicant .
Van Herwaadren et al., "The effect of baclofen on
gastro-oesophageal reflux, lower oesophageal sphincter function and
reflux symptoms in patients with reflux disease," Aliment.
Pharmacol. Ther. (2002) 16:1655-1662. cited by applicant .
Van Hilten et al., "Intrathecal baclofen for the treatment of
dystonia in patients with reflex sympathetic dystrophy," N Engl J
Med (2000) 343:625-630. cited by applicant .
Vela et al., "Baclofen decreases acid and non-acid post-prandial
gastro-oesophageal reflux measured by combined multichannel
intraluminal impedance and Ph," Aliment Pharmacol Ther (2003)
17:243-251. cited by applicant .
Von Heijne et al., "Effects of intrathecal morphine, baclofen,
clonidine and R-PIA on the acute allodynia-like behaviours after
spinal cord ischaemia in rats," Eur. J. Pain (2001), 5: 1-10. cited
by applicant .
Wall et al., "Autotomy following peripheral nerve lesions:
experimental anaesthesia dolorosa," Pain (1979), 7: 103-113. cited
by applicant .
Wright and Rang, "The spastic mouse and the search for an animal
model of spasticity in human beings," Clin. Orthop. Relat. Res.
(1990), 253: 12-19. cited by applicant .
Zhang et al., "Establishment of a spastic cerebral palsy model in
rats," Chin. J. Clin. Rehab. (2006), 10(38): 150-151. English
language abstract only. cited by applicant .
Zhang et aL, "Control of transient lower oesophageal sphincter
relaxations and reflux by the GABA.sub.B agonist baclofen in
patients with gastro-oesophageal reflux disease," Gut (2002)
50:19-24. cited by applicant .
Zuniga et al., "Intrathecal baclofen: a useful agent in the
treatment of well-established complex regional pain syndrome," Reg
Anesth Pain Med (2002) 27:90-93. cited by applicant .
PCT International Search Report and Written Opinion dated Nov. 19,
2012, PCT Appl. No. PCT/US2012/050379, 12 pages. cited by
applicant.
|
Primary Examiner: Hui; San-Ming
Assistant Examiner: Cruz; Kathrien
Attorney, Agent or Firm: Polsinelli PC
Parent Case Text
This application is a continuation of U.S. patent application Ser.
No. 13/572,367, filed Aug 10, 2012 (now U.S. Pat. No. 8,580,850),
which claims the benefit under 35 U.S.C. .sctn.119(e), of U.S.
Provisional Patent Application No. 61/508,286 filed Aug. 11, 2011,
the contents of which are incorporated herein by reference in their
entirety.
Claims
What is claimed is:
1. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate which exhibits
characteristic scattering angles (2.THETA.) at least at
4.33.degree..+-.0.2.degree., 4.76.degree..+-.0.2.degree.,
11.06.degree..+-.0.2.degree. and 11.61.degree..+-.0.2.degree. in an
X-ray powder diffractogram measured using Cu--K.sub..alpha.
radiation.
2. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1, comprising
characteristic scattering angles (2.THETA.) at least at
4.33.degree..+-.0.2.degree., 4.76.degree..+-.0.2.degree.,
5.83.degree..+-.0.2.degree., 9.07.degree..+-.0.2.degree.,
9.46.degree..+-.0.2.degree., 10.54.degree..+-.0.2.degree.,
11.06.degree..+-.0.2.degree., 11.61.degree..+-.0.2.degree.,
12.94.degree..+-.0.2.degree., 17.46.degree..+-.0.2.degree.,
17.84.degree..+-.0.2.degree., 18.01.degree..+-.0.2.degree.,
19.36.degree..+-.0.2.degree., 20.01.degree..+-.0.2.degree. and
21.26.degree..+-.0.2.degree. in an X-ray powder diffractogram
measured using Cu--K.sub..alpha. radiation.
3. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1, comprising
characteristic scattering angles (2.THETA.) at least at
4.33.degree..+-.0.2.degree., 4.76.degree..+-.0.2.degree.,
5.83.degree..+-.0.2.degree., 6.93.degree..+-.0.2.degree.,
9.07.degree..+-.0.2.degree., 9.46.degree..+-.0.2.degree.,
10.54.degree..+-.0.2.degree., 11.06.degree..+-.0.2.degree.,
11.61.degree..+-.0.2.degree., 12.94.degree..+-.0.2.degree.,
15.25.degree..+-.0.2.degree., 16.55.degree..+-.0.2.degree.,
17.46.degree..+-.0.2.degree., 17.84.degree..+-.0.2.degree.,
18.01.degree..+-.0.2.degree., 18.41.degree..+-.0.2.degree.,
18.69.degree..+-.0.2.degree., 18.93.degree..+-.0.2.degree.,
19.36.degree..+-.0.2.degree., 20.01.degree..+-.0.2.degree.,
20.46.degree..+-.0.2.degree., 21.26.degree..+-.0.2.degree.,
21.75.degree..+-.0.2.degree., 22.19.degree..+-.0.2.degree.,
22.56.degree..+-.0.2.degree., 23.35.degree..+-.0.2.degree.,
23.85.degree..+-.0.2.degree., 24.84.degree..+-.0.2.degree.,
25.96.degree..+-.0.2.degree., 26.78.degree..+-.0.2.degree.,
27.29.degree..+-.0.2.degree., 28.69.degree..+-.0.2.degree.,
29.39.degree..+-.0.2.degree., 31.22.degree..+-.0.2.degree.,
32.35.degree..+-.0.2.degree., 33.47.degree..+-.0.2.degree.,
34.62.degree..+-.0.2.degree. and 36.08.degree..+-.0.2.degree. in an
X-ray powder diffractogram measured using Cu--K.sub..alpha.
radiation.
4. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1, which exhibits a
strong characteristic Raman spectrum band at 119 cm.sup.-1.
5. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1, which exhibits
characteristic Raman spectrum bands at least at 119 cm.sup.-1 and
85 cm.sup.-1.
6. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1, which exhibits
characteristic Raman spectrum bands at least at 1599 cm.sup.-1,
1447 cm.sup.-1, 798 cm.sup.-1, 119 cm.sup.-1 and 85 cm.sup.-1.
7. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1, which exhibits
characteristic Raman spectrum bands at least at 1747 cm.sup.-1,
1599 cm.sup.-1, 1447 cm.sup.-1, 1412 cm.sup.-1, 1335 cm.sup.-1,
1203 cm.sup.-1, 1092 cm.sup.-1, 954 cm.sup.-1, 868 cm.sup.-1, 798
cm.sup.-1, 637 cm.sup.-1, 401 cm.sup.-1, 348 cm.sup.-1, 317
cm.sup.-1, 244 cm.sup.-1, 119 cm.sup.-1 and 85 cm.sup.-1.
8. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1, which has a
critical water activity of less than or equal to about
0.75.+-.0.05.
9. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1, which undergoes
thermal decomposition at a temperature ranging from about
170.degree. C. to about 190.degree. C. using a thermogravimetric
analyzer coupled with a Fourier-transform infrared spectrometer at
a scan rate of about 10 K/min.
10. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1, which undergoes
a melt/phase transition at a temperature ranging from about
120.degree. C. to about 140.degree. C. using differential scanning
calorimetry at a heating rate of 20 K/min.
11. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 10, wherein the
melt/phase transition occurs at about 131.degree. C. using
differential scanning calorimetry at a heating rate of 20
K/min.
12. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 10, wherein the
melt/phase transition occurs at about 131.3.degree. C. using
differential scanning calorimetry at a heating rate of 20
K/min.
13. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1, which contains
less than about 0.05 wt % water at 50% relative humidity as
measured by dynamic vapor sorption.
14. The crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1, which contains
less than about 0.1 wt % water at 95% relative humidity as measured
by dynamic vapor sorption.
15. A pharmaceutical composition comprising the crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate of claim 1 and a
pharmaceutically acceptable vehicle.
16. The pharmaceutical composition of claim 15, wherein the
pharmaceutical composition is a sustained release oral dosage
formulation.
Description
FIELD
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical
compositions comprising such compounds, methods of making such
compounds and methods of using such compounds are disclosed.
BACKGROUND
In general, crystalline forms of drugs are utilized in dosage forms
rather than amorphous forms of drugs, in part, because of their
superior stability. For example, in many situations, an amorphous
drug converts to a crystalline drug form upon storage. Because
amorphous and crystalline forms of a drug typically have different
physical/chemical properties, potencies and/or bioavailabilities,
such interconversion is undesirable for safety reasons in
pharmaceutical administration.
Polymorphs are crystals of the same molecule which have different
physical properties because the crystal lattice contains a
different arrangement of molecules. For example, certain polymorphs
can include different hydration states that incorporate water into
the crystalline structure without chemical alteration of the
molecule itself. In that regard, certain compounds can exist in
anhydrous and hydrated forms, where the hydrated forms can include,
for example, hydrates, dihydrates, trihydrates, and the like, or
partial hydrates such as hemihydrates. The different physical
properties exhibited by polymorphs can affect important
pharmaceutical parameters such as storage, stability,
compressibility, density (important in formulation and product
manufacturing) and dissolution rates (important in determining
bioavailability). Stability differences may result from changes in
chemical reactivity (e.g., differential hydrolysis or oxidation,
such that a dosage form discolors more rapidly when the dosage form
contains one polymorph rather than another polymorph), mechanical
changes (e.g., tablets crumble on storage as a kinetically favored
crystalline form converts to a thermodynamically more stable
crystalline form) or both (e.g., tablets of one polymorph are more
susceptible to breakdown at high humidity). Solubility differences
between polymorphs may, in extreme situations, result in
transitions to crystalline forms that lack potency and/or are
toxic. In addition, the physical properties of a particular
crystalline form may be important in pharmaceutical processing. For
example, one particular crystalline form may form solvates more
readily or may be more difficult to filter and wash free of
impurities than other forms (e.g., particle shape and size
distribution might be different between one crystalline form
relative to other forms).
Regulatory agencies such as the United States Food and Drug
Administration closely regulate the polymorphic content of the
active component of a drug in solid dosage forms. In general,
regulatory agencies require batch-by-batch monitoring for
polymorphic drugs if anything other than the pure,
thermodynamically preferred polymorph is marketed. Accordingly,
medical and commercial reasons favor synthesizing and marketing the
most thermodynamically stable polymorph of a crystalline drug
substance in solid drugs, which is substantially free of other,
less favored polymorphs.
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid, (1),
##STR00001## is a prodrug of the GABA.sub.B agonist, (R)-baclofen.
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid, (1) exhibits high bioavailability as
R-baclofen when dosed either orally or directly into the colon of a
mammal (see, for example, Gallop et al., U.S. Pat. Nos. 7,109,239
and 7,227,028).
SUMMARY
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate are disclosed.
In a first aspect, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, which exhibits
characteristic scattering angles (2.theta.) at least at
4.04.degree..+-.0.2.degree., 6.47.degree..+-.0.2.degree.,
15.68.degree..+-.0.2.degree., 18.91.degree..+-.0.2.degree. and
22.42.degree..+-.0.2.degree. in an X-ray powder diffractogram
measured using Cu--K.sub..alpha. radiation, is provided.
In a second aspect, pharmaceutical compositions are provided
comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, which exhibits
characteristic scattering angles (2.theta.) at least at
4.04.degree..+-.0.2.degree., 6.47.degree..+-.0.2.degree.,
15.68.degree..+-.0.2.degree., 18.91.degree..+-.0.2.degree. and
22.42.degree..+-.0.2.degree. in an X-ray powder diffractogram
measured using Cu--K.sub..alpha. radiation and a pharmaceutically
acceptable vehicle.
In a third aspect, methods of preparing crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, which exhibits
characteristic scattering angles (2.theta.) at least at
4.04.degree..+-.0.2.degree., 6.47.degree..+-.0.2.degree.,
15.68.degree..+-.0.2.degree., 18.91.degree..+-.0.2.degree. and
22.42.degree..+-.0.2.degree. in an X-ray powder diffractogram
measured using Cu--K.sub..alpha. radiation are provided, by steps
comprising providing a solution comprising
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl-2-methylpropa-
noate prepared as a racemic mixture, (R)-baclofen, water and a
solvent; and adjusting the temperature of the solution or
suspension to provide crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate.
In a fourth aspect, methods of treating a disease or disorder in a
patient are provided comprising administering to a patient in need
of such treatment a therapeutically effective amount of a
pharmaceutical composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, wherein the disease or
disorder is selected from spasticity, gastroesophageal reflux
disease, emesis, cough, substance addiction and abuse, neuropathic
pain and musculoskeletal pain.
In a fifth aspect, kits are provided comprising a pharmaceutical
composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating a disease or disorder chosen from selected
from spasticity, gastroesophageal reflux disease, emesis, cough,
substance addiction and abuse, neuropathic pain and musculoskeletal
pain.
In a sixth aspect, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, which exhibits
characteristic scattering angles (2.theta.) at least at
4.33.degree..+-.0.2.degree., 4.76.degree..+-.0.2.degree.,
11.06.degree..+-.0.2.degree. and 11.61.degree..+-.0.2.degree. in an
X-ray powder diffractogram measured using Cu--K.sub..alpha.
radiation, is provided.
In a seventh aspect, pharmaceutical compositions are provided
comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, which exhibits
characteristic scattering angles (2.theta.) at least at
4.33.degree..+-.0.2.degree., 4.76.degree..+-.0.2.degree.,
11.06.degree..+-.0.2.degree. and 11.61.degree..+-.0.2.degree. in an
X-ray powder diffractogram measured using Cu--K.sub..alpha.
radiation and a pharmaceutically acceptable vehicle.
In a eighth aspect, methods of preparing crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, which exhibits
characteristic scattering angles (2.theta.) at least at
4.33.degree..+-.0.2.degree., 4.76.degree..+-.0.2.degree.,
11.06.degree..+-.0.2.degree. and 11.61.degree..+-.0.2.degree. in an
X-ray powder diffractogram measured using Cu--K.sub..alpha.
radiation are provided, by steps comprising providing a solution
comprising
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl-2-methylpropa-
noate prepared as a racemic mixture, (R)-baclofen, water and a
solvent; adjusting the temperature of the solution or suspension to
provide crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid; and converting crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate into crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate by drying and/or by
recrystallization.
In a ninth aspect, methods of treating a disease or disorder in a
patient are provided comprising administering to a patient in need
of such treatment a therapeutically effective amount of a
pharmaceutical composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, wherein the disease or
disorder is selected from spasticity, gastroesophageal reflux
disease, emesis, cough, substance addiction and abuse, neuropathic
pain and musculoskeletal pain.
In a tenth aspect, kits are provided comprising a pharmaceutical
composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating a disease or disorder chosen from selected
from spasticity, gastroesophageal reflux disease, emesis, cough,
substance addiction and abuse, neuropathic pain and musculoskeletal
pain.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows an X-ray powder diffractogram of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate.
FIG. 2 shows a Raman spectrum of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate in the region from 50 to
2000 cm.sup.-1.
FIG. 3 shows an X-ray powder diffractogram of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate.
FIG. 4 shows a Raman spectrum of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate in the region from 50 to
2000 cm.sup.-1.
DETAILED DESCRIPTION
Definitions
"Bioavailability" refers to the amount of a drug that reaches the
systemic circulation of a patient following administration of the
drug or prodrug thereof to the patient and may be determined by
evaluating, for example, the plasma or blood
concentration-versus-time profile for a drug. Parameters useful in
characterizing a plasma or blood concentration-versus-time curve
include the area under the curve (AUC), the time to maximum
concentration (T.sub.max), and the maximum drug concentration
(C.sub.max), where C.sub.max is the maximum concentration of a drug
in the plasma or blood of a patient following administration of a
dose of the drug or prodrug thereof to the patient, and T.sub.max
is the time to the maximum concentration (C.sub.max) of a drug in
the plasma or blood of a patient following administration of a dose
of the drug or prodrug thereof to the patient.
"Crystalline" means having a regularly repeating arrangement of
molecules.
"Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate" refers to a compound in
which crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid is not associated with water
molecules. Other chemical names for crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate include, without limitation,
anhydrous crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid.
"Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate" refers to a compound in
which crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid is associated with water molecules,
including fractional water molecules. For example, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may contain less than one
molar fraction of water, including fractional moles of water, per
mole of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid. In some embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate contains one-half of one
molar fraction of water per mole of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid. The molecules of water may be
incorporated into the crystal lattice or loosely bound to the
crystal lattice. In certain embodiments, the fractional equivalent
of one-half molecule of water per molecule of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid is incorporated into the crystalline
lattice and any additional water content is bound to the exterior
of the crystalline lattice.
"Disease" refers to a disease, disorder, condition, symptom, or
indication. This term is used interchangeably with the phrase
"disease or disorder."
"Dosage form" refers to a form of a formulation that contains an
amount of active agent or prodrug of an active agent, for example
the (R)-baclofen prodrug
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1), which can be administered to a
patient to achieve a therapeutic effect. An oral dosage form is
intended to be administered to a patient via the mouth and
swallowed. Examples of oral dosage forms include capsules, tablets,
and liquid suspensions. A dose of a drug may include one or more
dosage forms administered simultaneously or over a period of
time.
"Patient" includes mammals, such as for example, humans.
"Pharmaceutical composition" refers to a composition comprising at
least one compound provided by the present disclosure and at least
one pharmaceutically acceptable vehicle with which the compound is
administered to a patient.
"Pharmaceutically acceptable" refers to approved or approvable by a
regulatory agency of a federal or a state government, listed in the
U.S. Pharmacopeia, or listed in other generally recognized
pharmacopeia for use in mammals, including humans.
"Pharmaceutically acceptable vehicle" refers to a pharmaceutically
acceptable diluent, a pharmaceutically acceptable adjuvant, a
pharmaceutically acceptable excipient, a pharmaceutically
acceptable carrier, or a combination of any of the foregoing, with
which crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be administered to a
patient, which does not destroy the pharmacological activity
thereof, and which is nontoxic when administered in doses
sufficient to provide a therapeutically effective amount of one or
both of the compounds.
"Prodrug" refers to a derivative of an active compound (such as a
drug) that undergoes a transformation under the conditions of use,
such as within the body, to release the active compound or drug.
Prodrugs are frequently, but not necessarily, pharmacologically
inactive until converted into the active compound or drug. Prodrugs
can be obtained by bonding a promoiety (defined herein), typically
via a functional group, to a drug. For example, the (R)-baclofen
prodrug
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) is metabolized within a patient's
body to form the parent drug (R)-baclofen.
"Promoiety" refers to a group bonded to a drug, typically to a
functional group of the drug, via one or more bonds that are
cleavable under specified conditions of use. The bond(s) between
the drug and promoiety may be cleaved by enzymatic or non-enzymatic
means. Under the conditions of use, for example following
administration to a patient, the bond(s) between the drug and
promoiety may be cleaved to release the parent drug. The cleavage
of the promoiety may proceed spontaneously, such as via a
hydrolysis reaction, or may be catalyzed or induced by another
agent, such as by an enzyme, by light, by acid, or by a change of
or exposure to a physical or environmental parameter, such as a
change of temperature, pH, etc. The agent may be endogenous to the
conditions of use, such as an enzyme present in the systemic
circulation to which the prodrug is administered or the acidic
conditions of the stomach, or the agent may be supplied
exogenously. For example, the promoiety of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid is:
##STR00002##
"Sustained release" refers to release of a therapeutic or
preventive amount of a drug or an active metabolite thereof over a
period of time that is longer than that of an immediate release
formulation of the drug. For oral formulations, the term "sustained
release" typically means release of the drug within the
gastrointestinal tract lumen over a time period ranging, for
example, from about 2 to about 30 hours, and in certain
embodiments, over a time period ranging from about 4 to about 24
hours. Sustained release formulations achieve therapeutically
effective concentrations of the drug in the systemic circulation
over a prolonged period of time relative to that achieved by oral
administration of an immediate release formulation of the drug.
"Therapeutically effective amount" refers to the amount of a
compound that, when administered to a subject for treating a
disease or disorder, or at least one of the clinical symptoms of a
disease or disorder, is sufficient to affect such treatment of the
disease, disorder, or symptom. A "therapeutically effective amount"
can vary depending, for example, on the compound, the disease,
disorder, and/or symptoms of the disease or disorder, severity of
the disease, disorder, and/or symptoms of the disease or disorder,
the age, weight, and/or health of the patient to be treated, and
the judgment of the prescribing physician. A therapeutically
effective amount in any given instance can be readily ascertained
by those skilled in the art and/or is capable of determination by
routine experimentation.
"Treating" or "treatment" of any disease or disorder refers to
arresting or ameliorating a disease, disorder, or at least one of
the clinical symptoms of a disease or disorder, reducing the risk
of acquiring a disease, disorder, or at least one of the clinical
symptoms of a disease or disorder, reducing the development of a
disease, disorder or at least one of the clinical symptoms of the
disease or disorder, or reducing the risk of developing a disease
or disorder or at least one of the clinical symptoms of a disease
or disorder. "Treating" or "treatment" also refers to inhibiting
the disease or disorder, either physically, (e.g., stabilization of
a discernible symptom), physiologically, (e.g., stabilization of a
physical parameter), or both, and to inhibiting at least one
physical parameter which may or may not be discernible to the
patient. In certain embodiments, "treating" or "treatment" refers
to delaying the onset of the disease or disorder or at least one or
more symptoms thereof in a patient which may be exposed to or
predisposed to a disease or disorder even though that patient does
not yet experience or display symptoms of the disease or
disorder.
Reference is now made in detail to certain embodiments of
compounds, dosage forms, compositions, methods of synthesis and
methods of use. The disclosed embodiments are not intended to be
limiting of the claims. To the contrary, the claims are intended to
cover all alternatives, modifications, and equivalents.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) has the following structure:
##STR00003## The synthesis of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid has been previously described in
Gallop et al., U.S. Pat. Nos. 7,109,239 and 7,227,028, and in
Gallop et al., PCT Publication No. WO 2005/019163 (see, e.g., PCT
Publication No. WO 2005/019163, Example 82). A crystalline form of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid has also been previously described
(see, e.g., PCT Publication Nos. WO 2008/086492 and WO
2009/096985). It is believed that the crystalline form disclosed in
these publications is the anhydrate polymorph of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid. The x-ray powder diffractogram data
of the anhydrate presented in this disclosure has not been
previously described.
The inventors of the present disclosure have now discovered that a
hemihydrate form of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid exists. The hemihydrate polymorph is
also disclosed herein. Thus, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid can be prepared in more than one
polymorphic crystalline form.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid exists as a hemihydrate. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is a solid exhibiting a
highly ordered crystalline lattice as evidenced by an extensive
pattern of both low-angle and high-angle reflections within the
X-ray powder diffraction (XRPD) diffractogram.
Reference to crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate includes all possible
tautomeric forms of the conventional chemical structure for this
compound and all isotopically labeled derivatives of this compound
(e.g., .sup.2H, .sup.3H, .sup.13C, .sup.14C, .sup.15N, .sup.17O,
.sup.18O, etc.).
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate exhibits characteristic
scattering angles (2.theta.) at least at
4.04.degree..+-.0.2.degree., 6.47.degree..+-.0.2.degree.,
15.68.degree..+-.0.2.degree., 18.91.degree..+-.0.2.degree. and
22.42.degree..+-.0.2.degree. in an X-ray powder diffractogram
measured using Cu--K.sub..alpha. radiation.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate exhibits characteristic
scattering angles (2.theta.) at least at
4.04.degree..+-.0.2.degree., 6.47.degree..+-.0.2.degree.,
9.46.degree..+-.0.2.degree., 10.10.degree..+-.0.2.degree.,
10.87.degree..+-.0.2.degree., 12.88.degree..+-.0.2.degree.,
15.68.degree..+-.0.2.degree., 18.91.degree..+-.0.2.degree.,
19.96.degree..+-.0.2.degree., 20.23.degree..+-.0.2.degree.,
22.42.degree..+-.0.2.degree., 28.07.degree..+-.0.2.degree. and
28.53.degree..+-.0.2.degree. in an X-ray powder diffractogram
measured using Cu--K.sub..alpha. radiation.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate exhibits characteristic
scattering angles (2.theta.) at least at
4.04.degree..+-.0.2.degree., 6.47.degree..+-.0.2.degree.,
7.97.degree..+-.0.2.degree., 9.46.degree..+-.0.2.degree.,
10.10.degree..+-.0.2.degree., 10.87.degree..+-.0.2.degree.,
12.88.degree..+-.0.2.degree., 15.68.degree..+-.0.2.degree.,
16.72.degree..+-.0.2.degree., 18.16.degree..+-.0.2.degree.,
18.91.degree..+-.0.2.degree., 19.33.degree..+-.0.2.degree.,
19.96.degree..+-.0.2.degree., 20.23.degree..+-.0.2.degree.,
20.62.degree..+-.0.2.degree., 21.76.degree..+-.0.2.degree.,
22.42.degree..+-.0.2.degree., 23.55.degree..+-.0.2.degree.,
24.02.degree..+-.0.2.degree., 25.13.degree..+-.0.2.degree.,
25.61.degree..+-.0.2.degree., 26.09.degree..+-.0.2.degree.,
28.07.degree..+-.0.2.degree., 28.53.degree..+-.0.2.degree.,
29.87.degree..+-.0.2.degree., 30.45.degree..+-.0.2.degree.,
30.74.degree..+-.0.2.degree., 31.52.degree..+-.0.2.degree.,
32.60.degree..+-.0.2.degree., 35.94.degree..+-.0.2.degree. and
36.63.degree..+-.0.2.degree. in an X-ray powder diffractogram
measured using Cu--K.sub..alpha. radiation.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate exhibits the
characteristic scattering angles (2.theta.) in an X-ray powder
diffractogram measured using Cu--K.sub..alpha. radiation shown in
FIG. 1.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate exhibits a strong
characteristic Raman spectrum band at 110 cm.sup.-1.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate exhibits characteristic
Raman spectrum bands at least at 110 cm.sup.-1 and 84
cm.sup.-1.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate exhibits characteristic
Raman spectrum bands at least at 779 cm.sup.-1, 110 cm.sup.-1 and
84 cm.sup.-1.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate exhibits characteristic
Raman spectrum bands at least at 1744 cm.sup.-1, 1600 cm.sup.-1,
1453 cm.sup.-1, 1290 cm.sup.-1, 1238 cm.sup.-1, 1201 cm.sup.-1, 954
cm.sup.-1, 872 cm.sup.-1, 779 cm.sup.-1, 635 cm.sup.-1, 362
cm.sup.-1, 315 cm.sup.-1, 110 cm.sup.-1 and 84 cm.sup.-1.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate exhibits the
characteristic Raman spectrum in the region from 50 cm.sup.-1 to
2000 cm.sup.-1 shown in FIG. 2.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be characterized by
the presence of two phase changes upon thermal decomposition. For
example, in certain embodiments two points of thermal decomposition
can be observed via TG-FTIR analysis. Additionally, in certain
embodiments two melting point peaks can be observed using DSC
analysis. The first phase transition can be attributed to the loss
of water, which is characteristic of the hemihydrate polymorph. In
certain embodiments, both phase changes can be attributable to the
hemihydrate from of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is generated at room
temperature in an acetonitrile/water mixture having a critical
water activity (a.sub.wct) of greater than or equal to about
0.75.+-.0.05. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is generated at room
temperature in an acetonitrile/water mixture having a water
activity (a.sub.w) of about 0.8. In certain embodiments,
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is generated at room
temperature in an acetonitrile/water mixture having a a.sub.w of
about 0.9. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is generated at room
temperature in an acetonitrile/water mixture having a a.sub.w
selected from about 0.8 and about 0.9.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate undergoes thermal
decomposition and loses about 2.1% of its total weight at a
temperature ranging from about 80.degree. C. to about 130.degree.
C. using a thermogravimetric analyzer (TG) coupled with a
Fourier-transform infrared (FTIR) spectrometer at a scan rate of
about 10 K/min. In some embodiments, the 2.1% weight loss is
attributable to water loss.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate undergoes thermal
decomposition at a temperature ranging from about 170.degree. C. to
about 190.degree. C. using a thermogravimetric analyzer (TG)
coupled with a Fourier-transform infrared (FTIR) spectrometer at a
scan rate of about 10 K/min.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate undergoes a first thermal
decomposition at a temperature ranging from about 80.degree. C. to
about 130.degree. C., and undergoes a second thermal decomposition
at a temperature ranging from about 170.degree. C. to about
190.degree. C., using a thermogravimetric analyzer (TG) coupled
with a Fourier-transform infrared (FTIR) spectrometer at a scan
rate of about 10 K/min. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate loses about 2.1% of its
total weight during the first thermal decomposition. In some
embodiments, the 2.1% weight loss is attributable to water
loss.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate undergoes a melt/phase
transition at a temperature ranging from about 90.degree. C. to
about 110.degree. C. using differential scanning calorimetry at a
heating rate of 20 K/min. In certain embodiments the thermal
decomposition occurs at about 100.degree. C. and in certain
embodiments at about 99.8.degree. C. In certain embodiments,
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate undergoes a melt/phase
transition at a temperature ranging from about 105.degree. C. to
about 125.degree. C. using differential scanning calorimetry at a
heating rate of 20 K/min. In certain embodiments the thermal
decomposition occurs at about 115.degree. C. and in certain
embodiments at about 114.8.degree. C.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate undergoes a first
melt/phase transition at a temperature ranging from about
90.degree. C. to about 110.degree. C., and also undergoes a second
melt/phase transition at a temperature ranging from about
105.degree. C. to about 125.degree. C. using differential scanning
calorimetry at a heating rate of 20 K/min. In certain embodiments
the first thermal decomposition occurs at about 100.degree. C. and
the second thermal decomposition occurs at about 115.degree. C. In
certain embodiments the first thermal decomposition occurs at about
99.8.degree. C. and the second thermal decomposition occurs at
about 114.8.degree. C.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is hygroscopic. In certain
embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is slightly hygroscopic
above about 60% relative humidity. In certain embodiments,
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate comprises from about 2 wt
%-about 3 wt % water. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate contains about 2.15 wt %
water at 50% relative humidity as measured by dynamic vapor
sorption. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate contains about 3 wt %
water at 95% relative humidity as measured by dynamic vapor
sorption.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid exists as an anhydrate. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate is a solid exhibiting a
highly ordered crystalline lattice as evidenced by an extensive
pattern of both low-angle and high-angle reflections within the
X-ray powder diffraction (XRPD) diffractogram
Reference to crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate includes all possible
tautomeric forms of the conventional chemical structure for this
compound and all isotopically labeled derivatives of this compound
(e.g., .sup.2H, .sup.3H, .sup.13C, .sup.14C, .sup.15N, .sup.17O,
.sup.18O, etc.).
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate exhibits characteristic
scattering angles (2.theta.) at least at
4.33.degree..+-.0.2.degree., 4.76.degree..+-.0.2.degree.,
11.06.degree..+-.0.2.degree. and 11.61.degree..+-.0.2.degree. in an
X-ray powder diffractogram measured using Cu--K.sub..alpha.
radiation.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate exhibits characteristic
scattering angles (2.theta.) at least at
4.33.degree..+-.0.2.degree., 4.76.degree..+-.0.2.degree.,
5.83.degree..+-.0.2.degree., 9.07.degree..+-.0.2.degree.,
9.46.degree..+-.0.2.degree., 10.54.degree..+-.0.2.degree.,
11.06.degree..+-.0.2.degree., 11.61.degree..+-.0.2.degree.,
12.94.degree..+-.0.2.degree., 17.46.degree..+-.0.2.degree.,
17.84.degree..+-.0.2.degree., 18.01.degree..+-.0.2.degree.,
19.36.degree..+-.0.2.degree., 20.01.degree..+-.0.2.degree. and
21.26.degree..+-.0.2.degree. in an X-ray powder diffractogram
measured using Cu--K.sub..alpha. radiation.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate exhibits characteristic
scattering angles (2.theta.) at least at
4.33.degree..+-.0.2.degree., 4.76.degree..+-.0.2.degree.,
5.83.degree..+-.0.2.degree., 6.93.degree..+-.0.2.degree.,
9.07.degree..+-.0.2.degree., 9.46.degree..+-.0.2.degree.,
10.54.degree..+-.0.2.degree., 11.06.degree..+-.0.2.degree.,
11.61.degree..+-.0.2.degree., 12.94.degree..+-.0.2.degree.,
15.25.degree..+-.0.2.degree., 16.55.degree..+-.0.2.degree.,
17.46.degree..+-.0.2.degree., 17.84.degree..+-.0.2.degree.,
18.01.degree..+-.0.2.degree., 18.41.degree..+-.0.2.degree.,
18.69.degree..+-.0.2.degree., 18.93.degree..+-.0.2.degree.,
19.36.degree..+-.0.2.degree., 20.01.degree..+-.0.2.degree.,
20.46.degree..+-.0.2.degree., 21.26.degree..+-.0.2.degree.,
21.75.degree..+-.0.2.degree., 22.19.degree..+-.0.2.degree.,
22.56.degree..+-.0.2.degree., 23.35.degree..+-.0.2.degree.,
23.85.degree..+-.0.2.degree., 24.84.degree..+-.0.2.degree.,
25.96.degree..+-.0.2.degree., 26.78.degree..+-.0.2.degree.,
27.29.degree..+-.0.2.degree., 28.69.degree..+-.0.2.degree.,
29.39.degree..+-.0.2.degree., 31.22.degree..+-.0.2.degree.,
32.35.degree..+-.0.2.degree., 33.47.degree..+-.0.2.degree.,
34.62.degree..+-.0.2.degree. and 36.08.degree..+-.0.2.degree. in an
X-ray powder diffractogram measured using Cu--K.sub..alpha.
radiation.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate exhibits the characteristic
scattering angles (2.theta.) in an X-ray powder diffractogram
measured using Cu--K.sub..alpha. radiation shown in FIG. 3.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate exhibits a strong
characteristic Raman spectrum band at 119 cm.sup.-1.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate exhibits characteristic
Raman spectrum bands at least at 119 cm.sup.-1 and 85
cm.sup.-1.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate exhibits characteristic
Raman spectrum bands at least at 1599 cm.sup.-1, 1447 cm.sup.-1,
798 cm.sup.-1, 119 cm.sup.-1 and 85 cm.sup.-1.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate exhibits characteristic
Raman spectrum bands at least at 1747 cm.sup.-1, 1599 cm.sup.-1,
1447 cm.sup.-1, 1412 cm.sup.-1, 1335 cm.sup.-1, 1203 cm.sup.-1,
1092 cm.sup.-1, 954 cm.sup.-1, 868 cm.sup.-1, 798 cm.sup.-1, 637
cm.sup.-1, 401 cm.sup.-1, 348 cm.sup.-1, 317 cm.sup.-1, 244
cm.sup.-1, 119 cm.sup.-1 and 85 cm.sup.-1.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate exhibits the characteristic
Raman spectrum in the region from 50 cm.sup.-1 to 2000 cm.sup.-1
shown in FIG. 4.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate is generated at room
temperature in an acetonitrile/water mixture having a critical
water activity (a.sub.wct) of less than or equal to about
0.75.+-.0.05. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate is generated at room
temperature in an acetonitrile/water mixture having a water
activity (a.sub.w) of about 0.7. In certain embodiments,
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate is generated at room
temperature in an acetonitrile/water mixture having a a.sub.w of
about 0.6. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate is generated at room
temperature in an acetonitrile/water mixture having a a.sub.w of
about 0.5. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate is generated at room
temperature in an acetonitrile/water mixture having a a.sub.w of
about 0.4. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate is generated at room
temperature in an acetonitrile/water mixture having a a.sub.w of
about 0.3. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate is generated at room
temperature in an acetonitrile/water mixture having a a.sub.w
selected from about 0.7, about 0.6, about 0.5, about 0.4 and about
0.3.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate undergoes thermal
decomposition at a temperature ranging from about 170.degree. C. to
about 190.degree. C. using a thermogravimetric analyzer (TG)
coupled with a Fourier-transform infrared (FTIR) spectrometer at a
scan rate of about 10 K/min.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate undergoes a melt/phase
transition at a temperature ranging from about 120.degree. C. to
about 140.degree. C. using differential scanning calorimetry at a
heating rate of 20 K/min. In certain embodiments, the melt/phase
transition occurs at about 131.degree. C. and in certain
embodiments at about 131.3.degree. C.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate is not hygroscopic. In
certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate contains less than about
0.05 wt % water at 50% relative humidity as measured by dynamic
vapor sorption. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate contains less than about 0.1
wt % water at 95% relative humidity as measured by dynamic vapor
sorption.
Methods of Synthesis
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate can be synthesized by: (i)
forming a solution of diastereomers comprising
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid; (ii) selectively crystallizing the
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid diastereomer as a hemihydrate; and
(iii) separating the crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate diastereomer from the
solution. In certain embodiments, the solution is water-containing
or aqueous.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be converted into
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate by a method selected from
drying and recrystallization.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) can be synthesized
following the methods described in Scheme 1 and Scheme 2 below.
Additionally, the individual diastereomers of crystalline
(3R)-4-{[(.+-.)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-
-(4-chlorophenyl)butanoic acid can be separated efficiently via the
methods described in Scheme 1. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a) can be synthesized
following the methods described in Scheme 3 and Scheme 4 below.
##STR00004##
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) can be prepared by
steps comprising providing a solution or suspension comprising
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methylprop-
anoate (3) prepared as a racemic mixture of
(R)-1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methyl-
propanoate and
(S)-1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methyl-
propanoate, (R)-baclofen (2), water and a solvent; and adjusting
the temperature of the solution or suspension to provide
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4).
In certain embodiments, the solvent is selected from methyl
tert-butyl ether, acetonitrile, toluene, chlorobenzene,
methylcyclohexane, heptane, methanol, ethanol, diethyl ether,
tetrahydrofuran, tert-amyl methyl ether and combinations of the
foregoing. In certain embodiments, the solvent is methyl tert-butyl
ether. In certain embodiments, the solvent is not
dimethylsulfoxide, dimethylformamide, or n-methylpyrrolidine. In
certain embodiments, the solution is aqueous. In the exemplary
embodiment depicted in Scheme 1, the solvent is methyl tert-butyl
ether.
In certain embodiments, the solution comprises solvent in an amount
ranging from about 20 v/v %-about 50 v/v %. In certain embodiments,
the solution comprises solvent in an amount of about 35 v/v %. In
the exemplary embodiment depicted in Scheme 1, the solution
comprises methyl tert-butyl ether in an amount of about 35 v/v %.
In certain embodiments, the solution comprises water in an amount
ranging from about 50 v/v % to about 80 v/v %. In certain
embodiments, the solution comprises water in an amount of about 65
v/v %. In certain embodiments, the solution comprises about 35 v/v
% methyl tert-butyl ether and about 65% v/v water.
In certain embodiments, the combination and dissolution of
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methylprop-
anoate (3) prepared as a racemic mixture of
(R)-1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methyl-
propanoate and
(S)-1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methyl-
propanoate, and (R)-baclofen (2) in solution can be carried out at
elevated temperature, up to and including the boiling point of the
solvent used. Accordingly, in certain embodiments, racemic
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl-2-methylpropa-
noate (3) and (R)-baclofen (2) can be dissolved in a solution with
heating and optionally, with shaking and stirring. The heated
solution may be maintained at elevated temperature to ensure
complete dissolution of racemic
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl-2-met-
hylpropanoate (3) and (R)-baclofen (2). The heated solution may
also be filtered at elevated temperature to remove any undissolved
components. Then racemic
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl-2-methylpropa-
noate (3) and (R)-baclofen (2) react in the solution to yield
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4).
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can then be crystallized
out of solution leaving
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4) in solution. Crystallization of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can occur by any number of
conventional means and/or by the methods disclosed hereinbelow.
In certain embodiments, (R)-baclofen can be recycled from
diastereomer
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4) by hydrolysis of the
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4) remaining in solution according to
Scheme 2.
##STR00005##
In Scheme 2, the hydrolysis of
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4) yields (R)-baclofen (2),
isobutyric acid (5), isobutyraldehyde (6), and carbon dioxide. The
recycled (R)-baclofen (2) can then be reused in further syntheses
of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) via the method of
Scheme 1.
Hydrolysis can occur in one or two steps. In certain embodiments,
the hydrolysis of
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4) is achieved by adding a first
solution comprising an acid and water to the resultant
crystallization solution from Scheme 1; and thereafter adding a
base.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a) can be synthesized
following the methods described in Scheme 3 and Scheme 4 below.
##STR00006##
In Scheme 3, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) is dried to produce
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a). Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) may be produced, for
example, according to the methods described above.
Drying can occur via any conventional means including, for example,
air drying, drying under vacuum, drying at an elevated temperature,
or any combination of the foregoing. In certain embodiments, the
drying can be carried out at elevated temperature, up to but
excluding the melting or thermal decomposition temperature of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a). In some embodiments,
the drying can be carried out at a temperature range of about
30.degree. C. to below about 90.degree. C., and in certain
embodiments at a temperature range of about 40.degree. C. to
80.degree. C. In the exemplary embodiment depicted in Scheme 3, the
drying occurs at a temperature of about 70.degree. C.
The drying of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) yields crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a) as a white crystalline
solid.
##STR00007##
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) can be recrystallized
to crystallize
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a).
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a) can be prepared by
steps comprising providing a solution or suspension comprising
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) and a solvent; and
adjusting the temperature of the solution or suspension to provide
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a).
In certain embodiments, the solvent is selected from acetone,
hexane, methyl tert-butyl ether, acetonitrile, toluene,
chlorobenzene, methylcyclohexane, heptane, methanol, ethanol,
diethyl ether, tetrahydrofuran, tert-amyl methyl ether and
combinations of the foregoing. In certain embodiments, the solvent
is a combination of acetone and hexane. In the exemplary embodiment
depicted in Scheme 1, the solvent is a combination of acetone and
hexane.
In certain embodiments, the solution comprises solvent in an amount
ranging from about 70 v/v %-about 100 v/v %. In certain
embodiments, the solution comprises solvent in an amount of about
90 v/v %. In the exemplary embodiment depicted in Scheme 1, the
solution comprises a combination of acetone and hexane in an amount
of about 90 v/v %. In certain embodiments, the solution comprises
water in an amount ranging from about 0 v/v % to about 30 v/v %. In
certain embodiments, the solution comprises water in an amount of
about 15 v/v %. In certain embodiments, the solution comprises
about 90 v/v % of a combination of acetone and hexane and about 10%
v/v water.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) can be maintained at
ambient or room temperature to crystallize
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a). Ambient or room
temperature refers to a temperature to which humans are accustomed
or have become acclimatized. In certain embodiments, room
temperature includes temperatures in the range of about 20.degree.
C.-27.degree. C. and/or temperatures in the range of about
68.degree. F.-80.degree. F. In certain embodiments, room
temperature is 20.degree. C., in certain embodiments 25.degree. C.,
in certain embodiments 68.degree. F., and in certain embodiments
77.degree. F. Other methods known to those of skill in the
crystallization arts, (e.g., solvent evaporation, drowning,
chemical reaction, seeding with a small quantity of the desired
crystal form, etc.) may also be employed to crystallize
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a).
In certain embodiments, the recrystallization of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a) from a solution
comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) and a solvent can be
carried out at elevated temperature, up to and including the
boiling point of the solvent used. Accordingly, in certain
embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) can be dissolved in a
solvent by heating and optionally, with shaking and stirring. The
heated solution may be maintained at elevated temperature to ensure
complete dissolution of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b). The heated solution
may also be filtered at elevated temperature to remove any
undissolved components. Then
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a) crystallizes out of the
solution.
The recrystallization of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) yields crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a) as a white crystalline
solid.
Crystallization of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate
In certain embodiments, the solution comprising
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methylprop-
anoate (3) prepared as a racemic mixture of
(R)-1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methyl-
propanoate and
(S)-1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methyl-
propanoate, and (R)-baclofen (2) can be slowly cooled to
crystallize
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b). Compound (1b) may be
separated from
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4) and residual solvent by filtration
and/or drying under reduced pressure. In certain embodiments, the
solution can be cooled to a temperature ranging from about
0.degree. C. to about 25.degree. C. to crystallize
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b).
In certain embodiments, the solution comprising racemic
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl-2-methylpropa-
noate (3) and (R)-baclofen (2) can be maintained at ambient or room
temperature to crystallize
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b), which may be
separated from
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4) and residual solvent by filtration
and/or drying under reduced pressure. Ambient or room temperature
refers to a temperature to which humans are accustomed or have
become acclimatized. In certain embodiments, room temperature
includes temperatures in the range of about 20.degree.
C.-27.degree. C. and/or temperatures in the range of about
68.degree. F.-80.degree. F. In certain embodiments, room
temperature is 20.degree. C., in certain embodiments 25.degree. C.,
in certain embodiments 68.degree. F., and in certain embodiments
77.degree. F. Other methods known to those of skill in the
crystallization arts, (e.g., solvent evaporation, drowning,
chemical reaction, seeding with a small quantity of the desired
crystal form, etc.) may also be employed to crystallize
3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-
-chlorophenyl)butanoic acid hemihydrate (1b).
Crystallization of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) from the solution
affords crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) as a white
crystalline solid.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) can be prepared by
steps comprising providing a solution comprising
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl-2-methylpropa-
noate (3) prepared as a racemic mixture, (R)-baclofen (2), water
and methyl tert-butyl ether; and adjusting the temperature of the
solution to provide crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4).
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) can be prepared by
steps comprising providing a solution comprising
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl-2-methylpropa-
noate (3) prepared as a racemic mixture, (R)-baclofen (2), about
65% v/v water and about 35% v/v methyl tert-butyl ether; and
adjusting the temperature of the solution to provide crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4).
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) can be prepared by
steps comprising providing a first solution comprising
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl-2-methylpropa-
noate (3) prepared as a racemic mixture, (R)-baclofen (2), about
65% v/v water and about 35% v/v methyl tert-butyl ether; increasing
the temperature of the first solution to create a second solution
comprising
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4); and decreasing the temperature of
the second solution to provide crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4).
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4) is a diastereomer of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid. In certain embodiments, the solvent
or combination of solvents is selected so that
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4) remains in solution during
crystallization of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b). In this way,
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) can be readily
separated from the diastereomer
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4) in a single crystallization step.
Other methods known to those of skill in the crystallization arts,
(e.g., high performance liquid chromatography, reverse-phase high
performance liquid chromatography, extraction, distillation
extraction, chromatography, the use of immobilized sorbents, etc.)
may also be employed to separate crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) from the diastereomer
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (4).
As used herein, the terms solution and suspension are used
interchangeably and are meant to include embodiments in which a
compound is in a solvent or solvent mixture regardless of
solubility. A solvent combination can be such that a compound in
solution exhibits temperature-dependent solubility. In general,
solvent combinations in which a compound is soluble within a first
temperature range, and poorly soluble within a second temperature
range, can be used in the crystallization methods disclosed herein.
Mixtures of a "good" solvent and an "anti-solvent" can also be used
with temperature dependent solubilization, i.e., dissolving at
elevated temperature and crystallizing at room temperature.
Examples of suitable "good" solvents, i.e., solvents in which
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid is soluble, include methanol, ethanol,
isopropanol, acetone, methyl isobutyl ketone, tetrahydrofuran,
2-methyl tetrahydrofuran, 1,4-dioxane, 1,2-ethandiol,
1,2-propanediol, 2-methoxyethanol, 2-ethoxyethanol, and a mixture
of any of the foregoing. Examples of suitable "anti-solvents",
i.e., solvents in which
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid exhibits poor solubility, include
water, diethyl ether, diisopropyl ether, methyl t-butyl ether,
toluene, chlorobenzene, alkanes such as pentane, hexane, heptane,
octane, nonane, decane, undecane, dodecane, cis- or trans-decalin,
cyclohexane, methylcyclohexane, and a mixture of any of the
foregoing.
Therapeutic Uses
The high (R)-baclofen oral bioavailability following administration
of compound (1) favors the efficacious use of compound (1) in oral
dosage forms, including sustained-release oral dosage forms, and
the use of such oral dosage forms for treating diseases such as
spasticity and gastro-esophageal reflux disease (van Herwaarden et
al., Aliment. Pharmacol. Ther. 2002, 16(9), 1655-62; Ciccaglione
and Marzio, Gut 2003, 52(4), 464-70; Andrews et al., U.S. Pat. No.
6,117,908; and Fara et al., International Publication No. WO
02/096404); in promoting alcohol abstinence in alcoholics (Gessa et
al., International Publication No. WO 01/26638); in promoting
smoking cessation (Gessa et al., International Publication No. WO
01/08675); in reducing addiction liability of narcotic agents
(Robson et al., U.S. Pat. No. 4,126,684); in the treatment of
emesis (Bountra et al., U.S. Pat. No. 5,719,185); as an
anti-tussive for the treatment of cough (Kreutner et al., U.S. Pat.
No. 5,006,560); as well as for treating movement disorders such as
dystonia and hiccups; peripheral nerve disorders such as muscle
stimulation disorders; spinal cord disorders such as spastic
paraparesis; cranial nerve disorders such as glossopharyngeal
neuralgia and trigeminal neuralgia; multiple sclerosis; and
cerebral palsy.
The pharmacological activity of (R)-baclofen,
(R)-4-amino-3-(4-chlorophenyl)butanoic acid, is believed to be
effected through selective activation of GABA.sub.B receptors,
resulting in neuronal hyperpolarization. GABA.sub.B receptors are
located in laminae I-IV of the spinal cord, where primary sensory
fibers end. GABA.sub.B receptors are G-protein coupled receptors
that activate conductance by K.sup.+-selective ion channels and can
reduce currents mediated by Ca.sup.2+ channels in certain neurons.
Baclofen has a pre-synaptic inhibitory effect on the release of
excitatory neurotransmitters and also acts postsynaptically to
decrease motor neuron firing (see Bowery, Trends Pharmacol. Sci.
1989, 10, 401-407; and Misgeld et al., Prog. Neurobiol. 1995, 46,
423-462).
A principal pharmacological effect of baclofen in mammals is
reduction of muscle tone and consequently the drug is frequently
used in the treatment of spasticity. Spasticity is associated with
damage to the corticospinal tract and is a common complication of
neurological disease. Diseases and conditions in which spasticity
may be a prominent symptom include cerebral palsy, multiple
sclerosis, stroke, head and spinal cord injuries, traumatic brain
injury, anoxia, and neurodegenerative diseases. Patients with
spasticity complain of stiffness, involuntary spasm, and pain.
These painful spasms may be spontaneous or triggered by a minor
sensory stimulus, such as touching the patient.
Baclofen is also useful in controlling gastro-esophageal reflux
disease (van Herwaarden et al., Aliment. Pharmacol. Ther. 2002,
16(9), 1655-62; Ciccaglione and Marzio, Gut 2003, 52(4), 464-70;
Andrews et al., U.S. Pat. No. 6,117,908; and Fara et al.,
International Publication No. WO 02/096404); in promoting alcohol
abstinence in alcoholics (Gessa et al., International Publication
No. WO 01/26638); in promoting smoking cessation (Gessa et al.,
International Publication No. WO 01/08675); in reducing addiction
liability of narcotic agents (Robson et al., U.S. Pat. No.
4,126,684); in the treatment of emesis (Bountra et al., U.S. Pat.
No. 5,719,185); as an anti-tussive for the treatment of cough
(Kreutner et al., U.S. Pat. No. 5,006,560); in treating neuropathic
pain (see e.g., Fromm et al., Neurology 1981, 31(6), 683-7; and
Ringel and Roy, Ann Neurol 1987, 21(5), 514-5); and in treating
musculoskeletal pain (see e.g., Hering-Hanit, Cephalalgia 1999,
19(6), 589-591; Hering-Hanit and Gadoth, Headache 2000, 40(1),
48-51; Freitag, CNS Drugs 2003, 17(6), 373-81; Slonimski et al.,
Reg Anesth Pain Med 2004, 29(3), 269-76).
Accordingly, administering crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, both of which are the
(R)-baclofen prodrugs, to a patient can be expected to be useful in
treating diseases and disorders associated with the GABA.sub.B
receptor and/or any of the diseases and disorders (R)-baclofen is
known to treat.
The suitability of the (R)-baclofen prodrugs crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate in treating the
above-listed diseases may be determined by methods described in the
art (see, e.g., Bowery, Trends Pharmacol. Sci. 1989, 10, 401-407;
Misgeld et al., Prog. Neurobiol. 1995, 46, 423-462; van Herwaarden
et al., Aliment. Pharmacol. Ther. 2002, 16(9), 1655-62; Ciccaglione
and Marzio, Gut 2003, 52(4), 464-470; Andrews et al., U.S. Pat. No.
6,117,908; Fara et al., International Publication No. WO 02/096404;
Gessa et al., International Publication No. WO 01/26638; Gessa et
al., International Publication No. WO 01/08675); Robson et al.,
U.S. Pat. No. 4,126,684; Bountra et al., U.S. Pat. No. 5,719,185;
and Kreutner et al., U.S. Pat. No. 5,006,560; Katz, Am. J. Phys.
Med. Rehabil. 1988, 67(3), 108-16; Krach, J. Child Neurol. 2001,
16(1), 31-6; Bryans et al., International Publication No. WO
01/90052; Bryans et al., EP 1178034; Cundy et al., U.S. Application
Publication No. 2002/0151529; Gallop et al., U.S. Application
Publication No. 2003/0176398; Gallop et al., U.S. Application
Publication No. 2003/0171303; Gallop et al., U.S. Application
Publication No. 2004/0006132; and Raillard et al., U.S. Application
Publication No. 2004/0014940).
A suitable dose of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or a suitable dose of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate to be administered to a
patient in need of (R)-baclofen therapy may be estimated based on
the mass equivalent of (R)-baclofen and the enhanced oral
bioavailability of (R)-baclofen provided by crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate.
In various aspects, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or pharmaceutical
compositions comprising either of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, may be administered to a
patient, such as a human, suffering from treating a disease or
disorder chosen from spasticity, gastroesophageal reflux disease,
emesis, cough, substance addiction and abuse, neuropathic pain and
musculoskeletal pain.
Further, in certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or pharmaceutical
compositions comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, can be administered to a
patient, such as a human, as a preventative measure against various
diseases or disorders. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or pharmaceutical
compositions comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, may be administered as a
preventative measure to a patient having a predisposition for
spasticity, gastroesophageal reflux disease, emesis, cough,
substance addiction and abuse, neuropathic pain and musculoskeletal
pain. Accordingly, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or pharmaceutical
compositions comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, may be used for the
prevention of one disease or disorder and concurrently for the
treatment of another (e.g., prevention of spasticity while treating
a narcotic addiction; prevention of neuropathic pain while treating
gastroesophageal reflux disease).
Both crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be more efficacious
than the parent drug molecule (i.e. baclofen) in treating
spasticity, gastroesophageal reflux disease, emesis, cough,
substance addiction and abuse, neuropathic pain and musculoskeletal
pain because, when administered orally, the compound provides for
sustained therapeutically effective blood concentrations of
(.+-.)-4-amino-3-(4-chlorophenyl)butanoic acid. It is believed that
metabolites of both crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate are absorbed from the
gastrointestinal lumen into the blood by a different mechanism than
that by which baclofen and other known GABA analogs are absorbed.
For example, pregabalin is believed to be actively transported
across the gut wall by a carrier transporter localized in the human
small intestine. In contrast, the compounds disclosed herein,
and/or metabolites thereof are believed to be absorbed across the
gut wall along a greater portion of the gastrointestinal tract,
including the colon.
Because metabolites of both crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be absorbed throughout
the gastrointestinal tract, including the colon, both compounds can
be advantageously formulated in sustained release oral formulations
that provide for sustained release of one or both of the compounds
over a period of hours into the gastrointestinal tract. The ability
of both crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate to be used in sustained
release oral dosage forms can facilitate therapeutic regimens
having a reduced dosing frequency necessary to maintain a
therapeutically effective baclofen concentration in the blood.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, combinations thereof,
and/or pharmaceutical compositions thereof, can be administered to
a patient for treating a disease or disorder selected from
spasticity, gastroesophageal reflux disease, emesis, cough,
substance addiction and abuse, neuropathic pain and musculoskeletal
pain.
Spasticity
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate can be administered to a
patient to treat spasticity. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be administered to a
patient to treat spasticity.
Spasticity is estimated to affect about 500,000 people in the
United States and more than 12 million people worldwide. Spasticity
is an involuntary, velocity-dependent, increased resistance to
stretch. Spasticity is characterized by muscle hypertonia in which
there is increased resistance to externally imposed movement with
increasing speed of stretch (Lance et al., Trans Am. Neurol. Assoc.
1970, 95, 272-274; and Sanger et al., Pediatrics 2003, 111,
e89-e97). Spasticity can be caused by lack of oxygen to the brain
before, during, or after birth (cerebral palsy); physical trauma
(brain or spinal cord injury); blockage of or bleeding from a blood
vessel in the brain (stroke); certain metabolic diseases;
adrenolekodystrophy; phenylketonuria; neurodegenerative diseases
such as Parkinson's disease and amyotrophic lateral sclerosis; and
neurological disorders such as multiple sclerosis. Spasticity is
associated with damage to the corticospinal tract and is a common
complication of neurological disease. Diseases and conditions in
which spasticity may be a prominent symptom include cerebral palsy,
multiple sclerosis, stroke, head and spinal cord injuries,
traumatic brain injury, anoxia, and neurodegenerative diseases.
Patients with spasticity complain of stiffness, involuntary spasm,
and pain. These painful spasms may be spontaneous or triggered by a
minor sensory stimulus, such as touching the patient.
Symptoms of spasticity can include hypertonia (increased muscle
tone), clonus (a series of rapid muscle contractions), exaggerated
deep tendon reflexes, muscle spasms, scissoring (involuntary
crossing of the legs), deformities with fixed joints, stiffness,
and/or fatigue caused by trying to force the limbs to move
normally. Other complications include urinary tract infections,
chronic constipation, fever or other systemic illnesses, and/or
pressure sores. The degree of spasticity can vary from mild muscle
stiffness to severe, painful, and uncontrollable muscle spasms.
Spasticity may coexist with other conditions but is distinguished
from rigidity (involuntary bidirectional non-velocity-dependent
resistance to movement), clonus (self-sustaining oscillating
movements secondary to hypertonicity), dystonia (involuntary
sustained contractions resulting in twisting abnormal postures),
athetoid movement (involuntary irregular confluent writhing
movements), chorea (involuntary, abrupt, rapid, irregular, and
unsustained movements), ballisms (involuntary flinging movements of
the limbs or body), and tremor (involuntary rhythmic repetitive
oscillations, not self-sustaining). Spasticity can lead to
orthopedic deformity such as hip dislocation, contractures, or
scoliosis; impairment of daily living activities such as dressing,
bathing, and toileting; impairment of mobility such as inability to
walk, roll, or sit; skin breakdown secondary to positioning
difficulties and shearing pressure; pain or abnormal sensory
feedback; poor weight gain secondary to high caloric expenditure;
sleep disturbance; and/or depression that is secondary to lack of
functional independence.
Treatment of spasticity includes physical and occupational therapy
such as functional based therapies, rehabilitation, facilitation
such as neurodevelopmental therapy, proprioceptive neuromuscular
facilitation, and sensory integration; biofeedback: electrical
stimulation; and orthoses. Oral medications useful in treating
spasticity include baclofen, benzodiazepines such as diazepam,
dantrolene sodium; imidazolines such as clonidine and tizanidine;
and gabapentin. Intrathecal medications useful in treating
spasticity include baclofen. Chemodenervation with local
anesthetics such as lidocaine and xylocalne; type A botulinum toxin
and type B botulinum toxin; phenol and alcohol injection can also
be useful in treating spasticity. Surgical treatments useful in
treating spasticity include neurosurgery such as selective dorsal
rhizotomy; and orthopedic operations such as contracture release,
tendon or muscle lengthening, tendon transfer, osteotomy, and
arthrodesis.
The efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate for the treatment of
spasticity can be assessed using animal models of spasticity and in
clinically relevant studies of spasticity of different etiologies.
Animal models of spasticity are known (see e.g., Eaton, J Rehab Res
Dev 2003, 40(4), 41-54; Kakinohana et al., Neuroscience 2006, 141,
1569-1583; Ligresti et al., British J Pharm 2006, 147, 83-91; Zhang
et al., Chinese J Clin Rehab, 2006, 10(38), 150-151; Hefferan et
al., Neuroscience Letters 2006, 403, 195-200; and Li et al., J
Neurophysiol 2004, 92, 2694-2703). For example, animal models of
spasticity include: (a) the mutant spastic mouse (Chai et al.,
Proc. Soc. Exptl. Biol. Med. 1962, 109, 491); (b) the acute/chronic
spinally transected rat and the acute decerebrate rat (see e.g.,
Wright and Rang, Clin Orthop Relat Res 1990, 253, 12-19; Shimizu et
al., J Pharmacol Sci 2004, 96, 444-449; and Li et al., J
Neurophysiol 2004, 92, 2694-2703); (c) primary observation Irwin
Test in the rat (Irwin, Psychopharmacologia 1968, 13, 222-57); and
d) Rotarod Test in the rat and mouse (Dunham et al., J. Am. Pharm.
Assoc. 1957, 46, 208-09). Other animal models include spasticity
induced in rats following transient spinal cord ischemia
(Kakinohana et al., Neuroscience 2006, 141, 1569-1583; and Hefferan
et al., Neuroscience Letters 2006, 403, 195-200), spasticity in
mouse models of multiple sclerosis (Ligresti et al., British J
Pharmacol 2006, 147, 83-91); and spasticity in rat models of
cerebral palsy (Zhang et al., Chinese J Clin Rehabilitation 2006,
10(38), 150-151). The maximal electroshock seizure (MES) threshold
test in rodents is sensitive for detecting potential anticonvulsant
properties (Loscher and Schmidt, Epilepsy Res 1988, 2(3), 145-181).
In this model, anticonvulsant agents elevate the threshold to
electrically-induced seizures while proconvulsants lower the
seizure threshold.
The efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate for treating spasticity
may also be assessed in humans using double blind
placebo-controlled clinical trials (see e.g., Priebe et al., Spinal
Cord 1997, 35(3), 171-5; Gruenthal et al., Spinal Cord 1997,
35(10), 686-9; Tuszynski et al., Spinal Cord 2007, 45, 222-231 and
Steeves et al., Spinal Cord 2007, 45, 206-221 for examples of the
conduct and assessment of clinical trials for spasticity caused by
spinal cord injury). Clinical trial outcome measures for spasticity
include the Ashworth Scale, the modified Ashworth Scale, muscle
stretch reflexes, presence of clonus and reflex response to noxious
stimuli. Spasticity can be assessed using methods and procedures
known in the art such as a combination of clinical examination,
rating scales such as the Ashworth Scale, the modified Ashworth
scale the spasm frequency scale and the reflex score, biomechanical
studies such as the pendulum test, electrophysiologic studies
including electromyography, and functional measurements such as the
Fugl-Meyer Assessment of Sensorimotor Impairment scale. Other
measures can be used to assess spasticity associated with a
specific disorder such as the Multiple Sclerosis Spasticity Scale
(Hobart et al., Brain 2006, 129(1), 224-234).
Gastroesophageal Reflux Disease
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate can be administered to a
patient to treat gastroesophageal reflux disease. In certain
embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be administered to a
patient to treat gastroesophageal reflux disease.
Gastroesophageal reflux disease (GERD) is defined as chronic
symptoms or mucosal damage produced by abnormal reflux in the
esophagus. Symptoms of GERD include heartburn, esophagitis,
stictures, dysphagia, chronic chest pain, cough, hoarsness, voice
changes, chronic ear ache, burning chest pains, nausea, and
sinusitis.
Tonic contraction of the lower esophageal sphincter is the
principal factor preventing the reflux of gastric contents into the
esophagus. Transient lower esophageal sphincter relaxation (TLESR)
is the major mechanism underlying reflux in normal subjects and
patients with GERD. GABA.sub.B agonists such as R-baclofen have
been shown to reduce TLESRs in humans (Lidums et al.,
Gastroenterology 2000, 118(1), 7-13; Vela et al., Aliment Pharmacol
Ther 2003, 17(2), 243-51; Ciccaglione and Marzio, Gut 2003, 52(4),
464-70; and Zhang et al., Gut 2002, 50(1), 19-24). Reduction of the
frequency of TLESRs by baclofen is believed to be due to inhibition
of vagal afferents, information transfer between the nucleus
tractus solitarious and dorsal motor nucleus of the vagus, and
vagal efferent outflow (Hornby et al., Gastroenterol Clin N Am
2002, 31(4 Suppl), S11-S20).
More specifically,
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) has been shown to reduce reflux
episodes in clinical trials (Castell et al., Am J. Gastroenterology
2006, 101(suppl 2)(52), S59 and poster presentation at American
College of Gastroenterology 2006 Annual Meeting, Oct. 20-25, 2006,
Las Vegas, Nev.; and Castell et al., Gastroenterology 2007, suppl.
A, 486 and poster presentation at Digestive Disease Week Meeting,
May 19-24, 2007, Washington D.C.).
The efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate for treating GERD may be
assessed using animal models such as those described by Blackshaw
et al., Am. J. Physiol. 1999, 277, G867-G874; Lehmann et al.,
Gastroenterology 1999, 117, 1147-1154; and Stakeberg and Lehmann,
Neurogastroenterol. Mot. 1999, 11, 125-132; and in clinical
trials.
Emesis
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate can be administered to a
patient to treat emesis. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be administered to a
patient to treat emesis.
Nausea, vomiting, and retching are basic human protective reflexes
against the absorption of toxins as well as responses to certain
stimuli. Nausea is a subjectively unpleasant wavelike sensation in
the back of the throat or epigastrium associated with pallor or
flushing, tachycardia, and an awareness of the urge to vomit.
Sweating, excess salivation, and a sensation of being cold or hot
may also occur. Vomiting is characterized by contraction of the
abdominal muscles, descent of the diaphragm, and opening of the
gastric cardia, resulting in forceful expulsion of stomach contents
from the mouth. Retching involves spasmodic contractions of the
diaphragm and the muscles of the thorax and abdominal wall without
expulsion of gastric contents. Emesis is used herein to refer to
nausea, vomiting, and/or retching.
Baclofen has been shown to suppress the retching and vomiting
induced by morphine, thereby indicating the involvement of the
GABA.sub.B receptor in the emetic control pathway (Suzuki et al.,
Neuropharmacology 2005, 49(8), 1121-31). Baclofen has also been
shown to antagonize emesis induced by nicotine and motion in animal
models (Chan et al., Eur J Pharmacology 2007, 559(2-3),
196-201).
The efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate for treating emesis can be
assessed using appropriate animal models and using clinical trials.
For example, efficacy in treating emesis induced by
chemotherapeutic agents can be determined based on effects
indicative of emesis such as pica, gastric stasis, and reduced food
intake in rats, mice, or ferrets (see, e.g., Liu et al., Physiology
& Behavior, 2005, 85, 271-277; Endo et al., Biogenic Amines,
2004, 18(3-6), 419-434; and Malik et al., Eur. J. Pharmacol, 2007,
555, 164-173). In clinical trials, assessment instruments such as
the Duke Descriptive Scale, Visual Analog Scales, Morrow Assessment
of Nausea and Emesis, Rhodes Index of Nausea and Vomiting Form-2,
and Functional Living Index Emesis can be used to measure efficacy
(see, e.g., Rhodes et al., CA Cancer J Clin, 2001, 51, 232-248 and
references therein). In general, adequately controlled, double
blind placebo controlled trails may be used to evaluate efficacy in
humans.
Cough
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate can be administered to a
patient to treat cough. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be administered to a
patient to treat cough.
Cough reflex, elicited by activation of cough receptors located in
the respiratory tract, clears inhaled irritants and foreign
substances from the respiratory tract and, in conjunction with the
mucociliary system, can expel excessive airway secretion produced
under abnormal conditions from the respiratory tract. Cough can be
caused by mild acuate upper respiratory tract infections,
allergies, asthma, chronic obstructive pulmonary disease, lung
cancer, gastroesophageal reflux disease, post-nasal drip, and heart
or ear disorders. However, chronic non-productive cough having no
identifiable cause accounts for a significant percent of patients
presenting with cough. Chronic cough is associated with
exacerbation of asthmatic symptoms, rib fractures, breathlessness,
ruptured abdominal muscles, pneumothorax, syncope, second and third
degree heart block, and loss of consciousness. Persistent and
uncontrollable cough can lead to morbidity and severely impairs the
quality of life of these patients.
Cough includes acute and chronic cough of any type, etiology, or
pathogenesis, and in particular cough associated with laryngeal
sensory neuropathy.
The anti-tussive effects of baclofen are well-known (see e.g.,
Dicpinigaitis and Dobkin, Chest 1997, 111(4), 996-9; Dicpinigaitis
and Rauf, Respiration 1998, 65(1), 86-8; Dicpinigaitis et al., J
Clin Pharmacol 1998, 38(4), 364-7; and Kreutner et al., U.S. Pat.
No. 5,006,560 and International Publication No. WO 91/08740).
The efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate for treating cough can be
assessed using appropriate animal models and using clinical trials.
Animal models of cough are reviewed by Lewis et al., Pulmonary
Pharmacology & Therapeutics 2007, 20, 325-333.
Substance Addiction or Abuse
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate can be administered to a
patient to treat substance addiction or abuse. In certain
embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be administered to a
patient to treat substance addiction or abuse.
In clinical trials, (R)-baclofen has been shown to be effective in
treating cocaine addiction (Brebner et al., Alcohol &
Alcoholism 2002, 37(5), 478-84; and Haney et al.,
Neuropsychopharmacology 2006, 31, 1814-21); methamphetamine
dependence (Heinzerling et al., Drug Alcohol Depend 2006, 85(3),
177-84); opioid dependence (Assadi et al., BMC Psychiatry 2003,
3(16); and Ahmadi-Abhari et al., J Clin Pharm Therapeutics 2001,
26(1), 67-71); alcohol craving and intake (Addolorato et al.,
Alcohol & Alcoholism 2002, 37(5), 504-8; and Flannery et al.,
Alcohol Clin Exp Res 2004, 28(10), 1517-23); nicotine use (Markou
et al., Ann N.Y. Acad Sci 2004, 1025, 491-503); and drug addiction
generally (Cousins et al., Drug Alcohol Dependence 2002, 65(3),
209-20).
The efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate for treating substance
addiction and abuse can be assessed using animal models and in
clinical trials. Animal models of substance abuse disorders are
known (see e.g., Fattore et al., Alcohol & Alcoholism 2002,
37(5), 495-498 (nicotine); Spano et al., Neuropharmacology 2007,
52, 1555-1562 (opiate addiction); and Maccioni et al., Alcohol
2005, 36, 161-168 (alcohol abuse)).
Neuropathic Pain
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate can be administered to a
patient to treat neuropathic pain. In certain embodiments,
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be administered to a
patient to treat neuropathic pain.
It is estimated that neuropathic pain affects over 6 million
patients in the U.S. and Europe and over 26 million patients
worldwide. Neuropathic pain involves an abnormal processing of
sensory input usually occurring after direct injury or damage to
nerve tissue. Neuropathic pain is a collection of disorders
characterized by different etiologies including infection,
inflammation, disease such as diabetes and multiple sclerosis,
trauma or compression to major peripheral nerves, and chemical or
irradiation-induced nerve damage (Jensen et al., Eur J Pharmacol
2001, 429, 1-11). Neuropathic pain typically persists long after
tissue injury has resolved. Prodrugs of GABA.sub.B agonists
provided by the present disclosure can be used to treat neuropathic
pain. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be used to treat
neuropathic pain including, for example, post-herpetic neuralgia,
peripheral neuropathy, trigeminal neuralgia, painful diabetic
neuropathy, HIV-related neuropathic pain, cancer-related pain,
and/or fibromyalgia.
The International Association for the Study of Neuropathic Pain
defines neuropathic pain states as disorders that are characterized
by lesions or dysfunction of the neural system(s) which, under
normal conditions, transmit noxious information to the central
nervous system. The mechanisms underlying neuropathic pain
conditions are highly heterogeneous, however all types of
neuropathic pain are presumed to involve nerve injury and certain
common aberrations in somatosensory processing in the central
and/or peripheral nervous system (Baron, Nat Clin Pract Neurol
2006, 2, 95-106; and Beggs and Salter, Drug Dev Res 2006, 67,
289-301). Potential causes of neuropathic pain include physical
damage, infection, and chemical exposure. Neuropathic pain can be
generally classified as a focal/multifocal lesion of the peripheral
nervous system, e.g., post-herpetic neuralgia, a generalized lesion
of the peripheral nervous system, painful diabetic neuropathy,
HIV-related neuropathic pain, a lesion of the central nervous
system, or a more complex neuropathic disorder. Peripheral
neuropathic pain can arise as a consequence of trauma and surgery
related nerve injury, e.g., brachial plexus injury; entrapment
neuropathies such as lumbar disc compression, carpal tunnel
syndrome; disease-related neuropathies, e.g., diabetes and
HIV-AIDS; radiculopathy; complex regional pain syndrome; and/or
tumor growth leading to nerve compression or infiltration. Central
neuropathic pain can be the result of stroke, multiple sclerosis,
post-ischemic myelopathy; post-herpetic neuralgia; and/or
post-traumatic spinal cord injury.
An essential part of neuropathic pain is a partial or complete loss
of afferent sensory function and the paradoxical presence of
certain hyperphenomena in the painful area. The nerve tissue lesion
may be found in the brain, spinal cord, or the peripheral nervous
system. Symptoms vary depending on the condition and can manifest
as hyperalgesia (the lowering of pain threshold and an increased
response to noxious stimuli), allodynia (the evocation of pain by
non-noxious stimuli such as cold, warmth, or touch), hyperpathia
(an explosive pain response that is suddenly evoked from cutaneous
areas with increased sensory detection threshold when the stimulus
intensity exceeds sensory threshold), paroxysms (a type of evoked
pain characterized by shooting, electric, shock-like or stabbing
pain that occur spontaneously, or following stimulation by an
innocuous tactile stimulus or by a blunt pressure), paraesthesia
(abnormal but non-painful sensations, which can be spontaneous or
evoked, often described as pins and needles), dysesthesia (abnormal
unpleasant but not necessarily painful sensation, which can be
spontaneous or provoked by external stimuli), referred pain and
abnormal pain radiation (abnormal spread of pain), and wind-up like
pain and after sensations (the persistence of pain long after
termination of a painful stimulus).
Patients with neuropathic pain typically describe burning,
lancinating, stabbing, cramping, aching, and sometimes vice-like
pain. The pain can be paroxysmal or constant. Pathological changes
to the peripheral nerve(s), spinal cord, and brain have been
implicated in the induction and maintenance of chronic pain.
Patients suffering from neuropathic pain typically endure chronic,
debilitating episodes that are refractory to current
pharmacotherapies and profoundly affect their quality of life.
Currently available treatments for neuropathic pain, including
tricyclic antidepressants and gabapentin, typically show limited
efficacy in the majority of patients (Sindrup and Jensen, Pain
1999, 83, 389-400).
There are several types of neuropathic pain. A classification that
relates to the type of damage or related pathophysiology causing a
painful neuropathy includes neuropathies associated with mechanical
nerve injury such as carpal tunnel syndrome, vertebral disk
herniation, entrapment neuropathies, ulnar neuropathy, and
neurogenetic thoracic outlet syndrome; metabolic disease associated
neuropathies such as diabetic polyneuropathy; neuropathies
associated with neurotropic viral disease such as herpes zoster and
human immunodeficiency virus disease; neuropathies associated with
neurotoxicity such as chemotherapy of cancer or tuberculosis,
radiation therapy, drug-induced neuropathy, and alcoholic
neuropathy; neuropathies associated with inflammatory and/or
immunologic mechanisms such as multiple sclerosis, anti-sulfatide
antibody neuropathies, neuropathy associated with monoclonal
gammopathy, Sjogren's disease, lupus, vasculitic neuropathy,
polyclonal inflammatory neuropathies, Guillain-Barre syndrome,
chronic inflammatory demyelinating neuropathy, multifocal motor
neuropathy, paraneoplastic autonomic neuropathy, ganglinoic
acetylcholine receptor antibody autonomic neuropathy, Lambert-Eaton
myasthenic syndrome and myasthenia gravis; neuropathies associated
with nervous system focal ischemia such as thalamic syndrome
(anesthesia dolorosa); neuropathies associated with multiple
neurotransmitter system dysfunction such as complex regional pain
syndrome; neuropathies associated with chronic/neuropathic pain
such as osteoarthritis, low back pain, fibromyalgia, cancer bone
pain, chronic stump pain, phantom limb pain, and paraneoplastic
neuropathies; toxic neuropathies (e.g., exposure to chemicals such
as exposure to acrylamide, 3-chlorophene, carbamates, carbon
disulfide, ethylene oxide, n-hexane, methyl n-butylketone, methyl
bromide, organophosphates, polychlorinated biphenyls, pyriminil,
trichlorethylene, or dichloroacetylene), focal traumatic
neuropathies, phantom and stump pain, monoradiculopathy, and
trigeminal neuralgia; and central neuropathies including ischemic
cerebrovascular injury (stroke), multiple sclerosis, spinal cord
injury, Parkinson's disease, amyotrophic lateral sclerosis,
syringomyelia, neoplasms, arachnoiditis, and post-operative pain;
mixed neuropathies such as diabetic neuropathies (including
symmetric polyneuropathies such as sensory or sensorimotor
polyneuropathy, selective small-fiber polyneuropathy, and autonomic
neuropathy; focal and multifocal neuropathies such as cranial
neuropathy, limb mononeuropathy, trunk mononeuropathy,
mononeuropathy multiplex, and asymmetric lower limb motor
neuropathy) and sympathetically maintained pain. Other neuropathies
include focal neuropathy; glosopharyngeal neuralgia; ischemic pain;
trigeminal neuralgia; atypical facial pain associated with Fabry's
disease, Celiac disease, hereditary sensory neuropathy, or
B12-deficiency; mono-neuropathies; polyneuropathies; hereditary
peripheral neuropathies such as Carcot-Marie-Tooth disease,
Refsum's disease, Strumpell-Lorrain disease, and retinitis
pigmentosa; acute polyradiculoneuropathy; and chronic
polyradiculoneuropathy. Paraneoplastic neuropathies include
paraneoplastic subacute sensory neuropathy, paraneoplastic motor
neuron disease, paraneoplastic neuromyotonia, paraneoplastic
demyelinating neuropathies, paraneoplastic vasculitic neuropathy,
and paraneoplastic autonomic insufficiency. Prodrugs of GABA.sub.B
agonists, such as crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, can be used to treat any
of the foregoing types of neuropathic pain. In certain embodiments,
the neuropathic pain is chosen from post-herpetic neuralgia,
peripheral neuropathy, trigeminal neuralgia, painful diabetic
neuropathy, HIV-related neuropathic pain, cancer-related pain, and
fibromyalgia. In certain embodiments, the neuropathic pain is
chosen from post-herpetic neuralgia and trigeminal neuralgia.
The GABA.sub.B agonist (R)-baclofen has long been known to have
antinociceptive activity in models of acute pain and recent studies
have shown that baclofen inhibits allodynia and hyperalgesia in the
chronic constriction injury and spinal nerve ligation models of
persistent neuropathic pain at doses lower than those required to
produce sedation and impairment of motor activity (see e.g., Hwang
and Yaksh, Pain 1997, 70(1), 15-22; Smith et al., Neruopharmacology
1994, 33(9), 1103-8; Patel et al., Pain 2001, 90(3), 217-26;
Balerio and Rubio, Pharmacol Res 2002, 46(3), 281-6; and Reis and
Duarte, Br J Pharmacol 2006, 149(6), 733-9).
In clinical studies, intrathecal baclofen administration has been
shown to be effective in treating neuropathic pain associated with
spinal-cord injury and multiple sclerosis (Herman et al., Clin J
Pain 1992, 8(4), 338-45), painful extremity paresthesias (Gatscher
et al., Acta Neurochir Suppl 2002, 79, 75-76), sympathetically
maintained pain (Van Hilten et al., N Engl J Med 2000, 343(9),
625-30; Becker et al., J Clin Neurosci 2000, 7(4), 316-9; and
Zuniga et al., Reg Anesth Pain Med 2002, 27(1), 90-3). GABA.sub.B
agonists such as baclofen have also been shown to be effective in
trigeminal, gloospharyngeal, vagoglossopharyngeal, and
ophthalmic-postherpetic neuralgias (Fromm et al., Neurology 1981,
31(6), 683-7; and Ringel and Roy, Ann Neurol 1987, 21(5), 514-5);
and in patients with diabetic neuropathy (Anghinah et al., Muscle
Nerve 1994, 17(8), 958-59). Doses of baclofen from about 50 mg/day
to about 60 mg/day have been shown to be effective in treating
trigeminal neuralgia (Fromm et al., Ann Neurol 1984, 15(3),
240-4).
The efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate for treating one or more
types of neuropathic pain can be assessed in animal models of
neuropathic pain and in clinical trials (see e.g., Beggs and
Salter, Drug Dev Res 2006, 67, 829-301). Useful animal models of
neuropathic pain include peripheral nerve injury by ligation or
transection including dorsal rhizotomy (Lombard et al., Pain 1979,
6(2), 163-174); spinal nerve ligation (Kim and Chung, Pain 1992,
50, 355-363; and Hwang and Yaksh, Pain 1997, 70(1), 15-22); sciatic
nerve transaction (Wall et al., Pain 1979, 7, 103-111); sciatic
nerve cuff (Mosconi and Kruger, Pain 1996, 64, 37-57); partial
nerve ligation (Seltzer et al., Pain 1990, 43, 205-218); chronic
constriction (Bennett and Xie, Pain 1988, 33, 87-107); rat spinal
cord ischemia model (Hao et al., Pain 1991, 45, 175-185; and von
Heijne et al., Eur J Pain 2001, 5, 1-10); and spared nerve injury
(Decosterd and Woolf, Pain 2000, 87, 149-158). Other animal models
of neuropathies involving immune system activation and metabolic
and chemically induced neuropathies include sciatic cyroneurolysis
(DeLeo et al., Pain 1994, 56, 9-16); zymosan-induced neuritis
(Chacur et al., Pain 2001, 94, 231-244); HIV gp120-induced pain
model (Herzberg and Sagen, J Neuroimmunol 2001, 116, 29-39);
photochemical ischemia (Kupers et al., Pain 1998, 76(1-2), 45-59);
anti-ganglioside antibody (Slart et al., Pain 1997, 69, 119-125);
streptozotocin-neuropathy (Fox et al., Pain 1999, 81, 307-316);
DDI-induced myelinopathy (Joseph et al., Pain 2004, 107, 147-158);
formalin phase 2 model of hyperalgesic pain (Dirig and Yaksy, J
Pharmacology Exper Ther 1995, 275, 219-227); vincristine-induced
pain model (Aley et al., Neuroscience 1996, 73, 259-265);
paclitaxel-induced pain model (Cavaletti et al., Exp Neurol 1995,
133, 64-72); and cisplatin-induced pain model (Authier et al.,
Neurosci Lett 2000, 25, 2576-2585).
The efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate for treating various types
of neuropathic pain can also be assessed in clinical trials using,
for example, randomized double-blind placebo controlled methods.
End points used in clinical trials for neuropathic pain can be
determined using validated neuropathic pain criteria such as the
Brief Pain Inventory, Categorical Scale, Gracety Pain Scale, Likert
Scale, Neuropathic Pain Scale, Numerical Pain Scale, Short Form
McGill Pain Questionnaire, Verbal Pain Scale, Visual Analog Scale
(VAS), VAS Pain Intensity Scale, and/or VAS Pain Relief Scale.
Musculoskeletal Pain
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate can be administered to a
patient to treat musculoskeletal pain. In certain embodiments,
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be administered to a
patient to treat musculoskeletal pain.
Musculoskeletal conditions causing tenderness, musculosketal pain
and muscle spasms include fibromyalgia, tension headaches,
myofascial pain syndrome, facet joint pain, internal disk
disruption, somatic dysfunction, spinal fractures, vertebral
osteomyelitis, polymyalgia rheumatica, atlantoaxial instability,
atlanto-occipital joint pain, osteoporotic vertebral compression
fracture, Scheuermann's disease, spondyloysis, spondylolisthesis,
kissing spines, sacroiliac joint pain, sacral stress fracture,
coccygodynia, failed back syndrome, and mechanical low back or neck
pain (see, e.g., Meleger and Krivickas, Neurol Clin 2007, 25,
419-438. In these conditions, muscle spasm is related to local
factors involving the affected muscle groups without the increased
tone or reflex characteristic of spasticity. Muscle, tendon,
ligament, intervertebral disc, articular cartilage, and bone can be
involved in musculoskeletal pain. Disorders that can produce neck
and back pain include muscle strain, ligament sprain, myofascial
pain, fibromyalgia, facet joint pain, internal disc disruption,
somatic dysfunction, spinal fracture, verterbral osteomyelitis, and
polymyalgia rheumatica, atlantoaxial instability and
atlanto-occipital joint pain. (see e.g., Meleger and Krivickas,
Neurological Clinics 2007, 25(2), 419-438).
Studies have shown that GABA.sub.B agonists can be effective in
treating muscular pain and/or spasms associated with peripheral
musculoskeletal conditions. Baclofen has been shown to be effective
in treating migraine (Hering-Hanit, Cephalalgia 1999, 19(6),
589-91; and Hering-Hanit and Gadoth, Headache 2000, 40(1), 48-51)
and specifically in tension-type headaches (Freitag, CNS Drugs
2003, 17(6), 373-81); and in low-back pain and radiculopathy
(Slonimski et al., Reg Anesth Pain Med 2004, 29(3), 269-76; Dapas
et al., Spine 1985, 10(4), 345-9; and Raphael et al., BMC
Musculoskeletal Disorders 2002, 3(17).
The efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate for treating one or more
types of musculoskeletal pain can be assessed in animal models of
neuropathic pain and in clinical trials. For example, Kehl et al.
disclose an animal model of muscle hyperplasia that employs
intramuscular injection of carrageenan as useful for assessing the
mechanisms and management of musculoskeletal pain (Kehl et al.,
Pain 2000, 85, 333-343).
Low back pain generally occurs in the lumbar region of the back in
the location of lumbar vertebrae L1-L5. Pain in the lower back can
be caused by a sprain, strain, or spasm to one of the muscles,
ligaments, facet joints, and/or sacroiliac joints in the back;
spinal sprain or overcompression; or disc rupture or bulge. Low
back pain may also reflect nerve or muscle irritation or bone
lesions. Most low back pain follows injury or trauma to the back,
but pain may also be caused by degenerative conditions such as
arthritis or disc disease, osteoporosis, or other bone diseases,
viral infections, irritation to joints and discs, or congenital
abnormalities in the spine. Obesity, smoking, weight gain during
pregnancy, stress, poor physical condition, posture inappropriate
for the activity being performed, and poor sleeping position also
may contribute to low back pain. Additionally, scar tissue created
when the injured back heals itself does not have the strength or
flexibility of normal tissue. Buildup of scar tissue from repeated
injuries eventually weakens the back and can lead to more serious
injury. Occasionally, low back pain may indicate a more serious
medical problem. Pain accompanied by fever or loss of bowel or
bladder control, pain when coughing, and progressive weakness in
the legs may indicate a pinched nerve or other serious condition.
People with diabetes may have severe back pain or pain radiating
down the leg related to neuropathy. Low back pain can be caused by
bulging disc(s) (e.g., protruding, herniated, or ruptured disc),
sciatica, spinal degeneration, spinal stenosis, osteoporosis,
osteoarthritis, compression fractures, skeletal irregularities,
fibromyalgia, spondylolysis and/or spondylolisthesis. Less common
spinal conditions that can cause low back pain include ankylosing
spondylitis, bacterial infections, osteomyelitis, spinal tumors,
Paget's disease, and Scheuermann's disease. Clinical results
suggest that GABA.sub.B agonists such as baclofen can be effective
in treating low back pain (Dapas et al., Spine 1985, 10(4), 345-9;
and Raphael et al., BMC Musculoskeletal Disorders 2002, 3(17). For
example, doses of baclofen from about 20 mg/day to about 80/mg day
have been shown to be effective in treating acute low back pain
(Dapas et al., Spine 1985, 10(4), 345-9).
In certain embodiments, methods of treating low back pain provided
by the present disclosure comprises treating disorders, conditions,
and/or symptoms associated with low back pain such as muscle
spasms. Symptoms of low back pain can depend on the cause. For
example, symptoms of back sprain or back strain include muscle
spasms, cramping, stiffness, and pain centered in the back and
buttocks. Symptoms of nerve-root pressure include leg pain, also
referred to as sciatica, and nerve-related manifestations such as
tingling, numbness, or weakness in one leg or in the foot, lower
leg, or both legs. Symptoms of arthritis of the spine include pain
and stiffness that are worse in the back and hip.
Fibromyalgia is a condition characterized by aching and pain in
muscles, tendons and joints all over the body, but especially along
the spine. The body also is tender to touch in specific areas
referred to as tender or trigger points. Other symptoms of
fibromyalgia include sleep disturbance, depression, daytime
tiredness, headaches, alternating diarrhea and constipation,
numbness and tingling in the hands and feet, feelings of weakness,
memory difficulties, and dizziness. Although the etiology of
fibromyalgia is not known, stress, disordered sleep patterns,
abnormal production of pain-related chemicals in the nervous
system, and/or low levels of growth hormone are believed to
contribute to the onset of fibromyalgia.
Fibromyalgia usually occurs in people between 20 and 60 years of
age and is estimated to affect 3.4% of women and 0.5% of men. The
incidence of juvenile primary fibromyalgia in school age girls is
estimated to be about 1.2%.
Current treatment of fibromyalgia is based on symptoms, with the
goals of alleviating pain, restoring sleep, and improving general
quality of life. Several nonpharmacologic treatments include
exercise, education, behavioral therapy and physical therapy.
Pharmacologic treatments include tricyclic compounds, serotonin
reuptake inhibitors, analgesics, muscle relaxants, and
acetylcholine esterase inhibitors. There is evidence suggesting
that GABA.sub.B agonists such as baclofen may be useful in
improving fibromyalgia symptoms (Taylor-Gjevre and Gjevre, Lupus
2005, 14(6), 486-8).
The efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate for treating fibromyalgia
may be assessed using animal models of fibromyalgia and in clinical
results (see e.g., Dooley et al., U.S. Patent Application
Publication Nos. 2004/0180959 and 2004/0138305; Crofford et al.,
Arthritis & Rheumatism 2005, 52, 4, 1264-1273; Eaton, J
Rehabilitation Research and Development 2003, 40(4), 41S-54S; Guay,
Am J Geriatr Pharmacother 2005, 3, 274-287; Freynhagen et al., Pain
2005, 115, 254-263; Backonja et al., Clin Ther. 2003, 25, 81-104;
Gidal et al., Am J Manag Care. 2006, 12, S269-S278; and Argoff,
JAOA, 2002, Suppl. 3, 102(9), S21-S26). In particular, animal
models of neuropathic pain or clinically relevant studies of
different types of neuropathic pain have been found useful in
assessing therapeutic activity for treating fibromyalgia, such as
are disclosed, for example, in Bennett and Xie, Pain 1988, 33,
87-107; Chaplan et al., J. Neurosci. Meth. 1994, 53, 55-63; Fox et
al., Pain 2003, 105, 355-362; Milligan et al., Brain Res. 2000,
861, 105-116; De Vry et al., Eur. J. Pharmacol. 2004, 491, 137-148;
and Polomano et al., Pain 2001, 94, 293-304.
Modes of Administration
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, may be advantageously used in human medicine.
Additionally, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, may be advantageously used in human medicine.
As disclosed herein, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, are useful for the treatment of spasticity,
gastroesophageal reflux disease, emesis, cough, substance addiction
and abuse, neuropathic pain and musculoskeletal pain.
When used to treat the above diseases, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, may be administered or applied singly, or in
combination with other agents. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, may also be administered or applied singly or
in combination with other pharmaceutically active agents, including
other GABA analogs.
Methods of treatment include administering to a patient in need of
such treatment a therapeutically effective amount of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or administering to a patient in need of
such treatment a therapeutically effective amount of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof. The patient may be an animal, such as a
mammal, for example, a human.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can be administered orally. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, may also be administered by any other
convenient route, for example, by infusion or bolus injection, or
by absorption through epithelial or mucocutaneous linings (e.g.,
oral mucosa, rectal and intestinal mucosa, etc.). Administration
can be systemic or local. Various delivery systems are known,
(e.g., encapsulation in liposomes, microparticles, microcapsules,
capsules, etc.) that can be used to administer crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or that can be used to administer
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof. Methods of administration include, but are not
limited to, intradermal, intramuscular, intraperitoneal,
intravenous, subcutaneous, intranasal, epidural, oral, sublingual,
intranasal, intracerebral, intravaginal, transdermal, rectally, by
inhalation, or topically, particularly to the ears, nose, eyes or
skin.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, may be delivered via sustained release
systems, such as an oral sustained release system.
Both crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, exhibit enhanced bioavailability as
(R)-baclofen compared to the bioavailability of (R)-baclofen when
administered in an equivalent dosage form of R-baclofen and/or
racemate. The enhanced bioavailability of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, is believed to be due the efficient absorption
of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate throughout the
gastrointestinal tract, including the colon, via passive and/or
active transport mechanisms.
Both crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, provide (R)-baclofen upon in vivo
administration to a patient. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a metabolite thereof,
may be absorbed into the systemic circulation from the
gastrointestinal tract either by passive diffusion, active
transport or by both passive and active processes.
Following administration to a patient, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, provide (R)-baclofen in the systemic
circulation of a patient. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be absorbed from the
gastrointestinal tract and enter the systemic circulation where the
promoiety is cleaved to release (R)-baclofen.
When administered to a patient, for example, by a patient
swallowing a dosage form comprising the compounds disclosed herein,
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate provide a sustained
therapeutically effective concentration of (R)-baclofen in the
blood of a patient during a continuous period of time. In certain
embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may provide a
concentration of (R)-baclofen in the blood of a patient that is
greater than a minimum therapeutically effective concentration and
less than a minimum adverse concentration of (R)-baclofen in the
blood of the patient. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate provide a therapeutically
effective concentration of (R)-baclofen in the blood of a patient
for a continuous period of time without exceeding the minimum
adverse concentration of (R)-baclofen. In certain embodiments, the
concentration of (R)-baclofen in the blood of a patient does not
exceed a minimum adverse concentration at any time after
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is administered to a
patient.
The promoiety of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be cleaved either
chemically and/or enzymatically. One or more enzymes present in the
stomach, intestinal lumen, intestinal tissue, blood, liver, brain
or any other tissue of a mammal may cleave the promoiety of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate. The promoiety of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be cleaved prior to
absorption by the gastrointestinal tract (e.g., within the stomach
or intestinal lumen) and/or after absorption by the
gastrointestinal tract (e.g., in intestinal tissue, blood, liver or
other suitable tissue of a mammal). When the promoiety of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is cleaved prior to
absorption by the gastrointestinal tract, baclofen may be absorbed
into the systemic circulation conventionally (e.g., mediated, in
part, via the large neutral amino acid transporter located in the
small intestine). When the promoiety of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is cleaved after
absorption by the gastrointestinal tract, these baclofen prodrugs
may be absorbed into the systemic circulation either by passive
diffusion, active transport, or by both passive and active
processes.
When the promoiety of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is cleaved after
absorption by the gastrointestinal tract, these baclofen prodrugs
may be absorbed into the systemic circulation from the large
intestine. When absorbed by the large intestine, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can be advantageously administered as a
sustained release system. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can be delivered by oral sustained release
administration. When administered using a sustained release
formulation, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can be administered once per day, twice per
day, or in some embodiments more than twice per day.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can provide a
therapeutically effective concentration of (R)-baclofen in the
blood of a patient for a continuous period of time while reducing
or eliminating adverse drug effects associated with high blood
concentrations of (R)-baclofen, e.g., at concentrations above the
minimum adverse concentration, that are observed following dosing
of (R)-baclofen itself. The high bioavailability of (R)-baclofen
that is achievable by administering crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may facilitate the use of
lower mass equivalents of (R)-baclofen in a dose to achieve a
sustained therapeutically effective concentration of (R)-baclofen
in the blood of a patient, as compared to the amount of
(R)-baclofen in a dosage form comprising (R)-baclofen itself.
In certain embodiments, administration of a sustained release
dosage form comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can provide a
therapeutically effective concentration of
(R)-4-amino-3-(4-chlorophenyl)butanoic acid in the blood plasma of
a patient for a time period of at least about 4 hours after
administration of the dosage form, in certain embodiments for a
time period of at least about 8 hours, in certain embodiments for a
time period of at least about 12 hours, in certain embodiments for
a time period of at least about 16 hours, in certain embodiments
for a time period of at least about 20 hours, and in certain
embodiments, for a time period of at least about 24 hours.
In certain embodiments, the concentration of (R)-baclofen in the
blood of a patient will not exceed a minimum adverse concentration
at any time after crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is administered to the
patient. For example, the concentration of (R)-baclofen in the
blood of a patient will not reach a concentration that causes
adverse events in the patient. A therapeutically effective
concentration of (R)-baclofen in the blood of a patient may range
from about 50 ng/mL to about 1,000 ng/mL, and in certain
embodiments, from about 100 ng/mL to about 500 ng/mL. The
pharmacokinetic profile of the blood (R)-baclofen concentration
achievable upon administration of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate to a patient can be
characterized by a lower C.sub.max/C.sub.12 ratio, and a lower
C.sub.max/dose, as compared to formulations comprising (R)-baclofen
itself that provide a similar (R)-baclofen blood AUC.sub.inf.
Pharmaceutical Compositions
Pharmaceutical compositions provided by the present disclosure
contain crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate together with a suitable
amount of a pharmaceutically acceptable vehicle so as to provide a
form for proper oral administration to a patient. In certain
embodiments, pharmaceutical compositions provided by the present
disclosure contain a therapeutically effective amount of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate together with a suitable
amount of a pharmaceutically acceptable vehicle so as to provide a
form for proper oral administration to a patient. Suitable
pharmaceutical vehicles include excipients such as starch, glucose,
lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel,
sodium stearate, glycerol monostearate, talc, sodium chloride,
dried skim milk, glycerol, propylene, glycol, water, ethanol, etc.
Pharmaceutical compositions provided by the present disclosure may
also contain minor amounts of wetting or emulsifying agents or pH
buffering agents. In addition, auxiliary, stabilizing, thickening,
lubricating and coloring agents may be used.
Pharmaceutical compositions comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be manufactured by
means of mixing, dissolving, granulating, dragee-making,
levigating, emulsifying, encapsulating, entrapping, lyophilizing,
or other process known to those skilled in the art of
pharmaceutical formulation. Pharmaceutical compositions may be
formulated using one or more pharmaceutically acceptable vehicles
that facilitate processing crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate into oral dosage
formulations, such as sustained release oral dosage
formulations.
Pharmaceutical compositions provided by the present disclosure can
take the form of solutions, aqueous or oily suspensions, emulsion,
tablets, pills, pellets, capsules, capsules containing liquids,
granules, powders, sustained-release formulations, suppositories,
emulsions, syrups, elixirs or any other form suitable for oral
administration. Orally administered pharmaceutical compositions may
contain one or more optional agents, for example, sweetening agents
such as fructose, aspartame or saccharin, flavoring agents such as
peppermint, oil of wintergreen or cherry coloring agents and
preserving agents, to provide a pharmaceutically palatable
preparation. Moreover, where in tablet or pill form, the
pharmaceutical compositions may be coated to delay disintegration
and absorption in the gastrointestinal tract, thereby providing a
sustained action over an extended period of time. Selectively
permeable membranes surrounding an osmotically active driving
compound are also suitable for orally administering the compounds
and compositions disclosed herein. In these later platforms, fluid
from the environment surrounding the capsule is imbibed by the
driving compound, which swells to displace the agent or agent
composition through an aperture. These delivery platforms can
provide an essentially zero order delivery profile as opposed to
the spiked profiles of immediate release formulations. A time delay
material such as glycerol monostearate or glycerol stearate may
also be used. Oral pharmaceutical compositions can include
pharmaceutically acceptable vehicles such as mannitol, lactose,
starch, magnesium stearate, sodium saccharine, cellulose, magnesium
carbonate, and the like.
For oral liquid preparations such as, for example, suspensions,
elixirs and solutions, suitable vehicles include water, saline,
alkyleneglycols (e.g., propylene glycol), polyalkylene glycols
(e.g., polyethylene glycol) oils, alcohols, slightly acidic buffers
between pH 4 and pH 6 (e.g., acetate, citrate, ascorbate at between
about 5 mM to about 50 mM), etc. Additionally, flavoring agents,
preservatives, coloring agents, bile salts, acylcarnitines and the
like may be added.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be formulated in
rectal or vaginal compositions such as suppositories or retention
enemas, e.g., containing conventional suppository bases such as
cocoa butter or other glycerides.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be formulated as a
single active agent. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be formulated as a
mixture. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be formulates as a
mixture with one or more other baclofen prodrugs or salts thereof
such as, for example,
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonyla-
mino}-3-(4-chlorophenyl)butanoic acid.
Kits
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, may be included in a kit that may be used to
administer either compound, or both, to a patient for treating a
disease. A kit can include a pharmaceutical composition comprising
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate suitable for
administration to a patient and instructions for administering the
pharmaceutical composition to a patient. A kit can include one or
more containers for containing one or more pharmaceutical
compositions and may include divided containers such as a divided
bottle or a divided foil packet. A container can be any appropriate
shape or form made of a pharmaceutically acceptable material. A
particular container can depend on the dosage form and the number
of dosage forms provided. Instructions provided with a kit can
include directions for administration and may include a memory aid.
Instructions supplied with a kit may be printed and/or supplied,
for example, as an electronic-readable medium, a video cassette, an
audiotape, a flash memory device, or may be published on an
internet web site or distributed to a patient as an electronic
mail. A memory aid may be a written memory aid, which contains
information and/or instructions for the physician, pharmacist,
and/or patient to facilitate compliance with a dosing regimen. A
memory aid may also be mechanical or electronic. When a therapeutic
regimen includes administration of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and at least one other
therapeutic agent, a kit can include the at least one other
therapeutic agent in the same or separate container as the
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate.
In certain embodiments, a kit comprises a pharmaceutical
composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating a disease chosen from spasticity,
gastroesophageal reflux disease, emesis, cough, substance addiction
and abuse, neuropathic pain and musculoskeletal pain. In certain
embodiments, a kit comprises a pharmaceutical composition
comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating a disease chosen from spasticity,
gastroesophageal reflux disease, emesis, cough, substance addiction
and abuse, neuropathic pain and musculoskeletal pain.
In certain embodiments, a kit comprises a pharmaceutical
composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating spasticity. In certain embodiments, a kit
comprises a pharmaceutical composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating spasticity.
In certain embodiments, a kit comprises a pharmaceutical
composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating gastroesophageal reflux disease. In certain
embodiments, a kit comprises a pharmaceutical composition
comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating gastroesophageal reflux disease.
In certain embodiments, a kit comprises a pharmaceutical
composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating substance addiction or abuse. In certain
embodiments, a kit comprises a pharmaceutical composition
comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating substance addiction or abuse.
In certain embodiments, a kit comprises a pharmaceutical
composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating cough. In certain embodiments, a kit comprises
a pharmaceutical composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating cough.
In certain embodiments, a kit comprises a pharmaceutical
composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating emesis. In certain embodiments, a kit
comprises a pharmaceutical composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating emesis.
In certain embodiments, a kit comprises a pharmaceutical
composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating neuropathic pain. In certain embodiments, a
kit comprises a pharmaceutical composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating neuropathic pain.
In certain embodiments, a kit comprises a pharmaceutical
composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating musculoskeletal pain. In certain embodiments,
a kit comprises a pharmaceutical composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and instructions for
administering the pharmaceutical composition to a patient in need
thereof for treating musculoskeletal pain.
Dose
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can generally be used in an amount that is
effective to achieve the intended purpose, such as to treat a
disease or disorder selected from spasticity, gastroesophageal
reflux disease, emesis, cough, substance addiction and abuse,
neuropathic pain and/or musculoskeletal pain. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, can be administered in a therapeutically
effective amount. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can be administered in a therapeutically
effective amount.
The amount of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or the amount of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, that will be effective in the treatment of a
particular disease or disorder will depend on the nature of the
disorder or condition, and can be determined by standard clinical
techniques known in the art as previously described. In addition,
in vitro or in vivo assays may optionally be employed to help
identify optimal dosage ranges. The amount of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or the amount of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, administered will depend on, among other
factors, the subject being treated, the weight of the subject, the
severity of the affliction, the manner of administration and the
judgment of the prescribing physician.
A dose of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or a dose of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be adjusted to provide
an equivalent molar quantity or mass equivalent dose of
(R)-baclofen. A dose can comprise multiple dosage forms.
Therapeutically effective doses of (R)-baclofen are generally from
about 0.03 mg to about 1 mg per kilogram body weight per day. In
certain embodiments, a daily dose can comprise a mass equivalent of
(R)-baclofen ranging from about 1 mg to about 100 mg, in certain
embodiments, from about 5 mg to about 80 mg, in certain
embodiments, from about 5 mg to about 60 mg, and in certain
embodiments, from about 10 mg to about 40 mg. In certain
embodiments, a dose of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or a dose of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is less than a dose that
causes moderate sedation and impairment of motor activity in a
patient. The dose of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or the dose of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, and appropriate dosing
intervals, can be selected to maintain a sustained therapeutically
effective concentration of (R)-baclofen in the blood of a patient,
and in certain embodiments, without exceeding a minimum adverse
concentration.
A dose may be delivered in a pharmaceutical composition by a single
administration or by multiple applications of one or more dosage
forms. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can be delivered by oral sustained release
administration. A sustained release formulation comprising
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or a sustained release formulation
comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can be administered once per day, twice per
day and, in certain embodiments, at intervals greater than twice
per day. Dosing may be repeated intermittently, may be provided
alone or in combination with other drugs, and may continue as long
as required for effective treatment of the disease or disorder.
Dosing includes administering a dosage form to a mammal, such as a
human, in a fed or fasted state.
Appropriate dosage ranges for treating a particular disease may be
readily determined by methods known to the skilled artisan.
In certain embodiments, a dose or multiple doses of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or a dose or multiple doses of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can provide between about 10 mg/day and about
2,000 mg/day of (R)-baclofen, in certain embodiments between about
50 mg/day and about 1,000 mg/day of (R)-baclofen, and in certain
embodiments, between about 100 mg/day and about 600 mg/day of
(R)-baclofen.
In certain embodiments, a dose or multiple doses of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or a dose or multiple doses of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, is administered to a patient at a dose of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate ranging from about 5 mg to
about 140 mg, and in certain embodiments, from about 10 mg to about
120 mg. In certain embodiments, the dose of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate administered is less than
a dose of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate that causes moderate
sedation and impairment of motor activity in a patient.
A dosage regimen employing oral administration of a dose or
multiple doses of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or a dose or multiple doses of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, may be developed to maintain a concentration
of (R)-baclofen in the blood of a patient that is greater than a
minimum therapeutically effective concentration and less than a
minimum adverse concentration for a prolonged period of time. In
certain embodiments, a minimum therapeutically effective
concentration of (R)-baclofen may range from about 1 ng/mL to about
200 ng/mL, and in certain embodiments, can range from about 10
ng/mL to about 100 ng/mL. In certain embodiments, a minimum adverse
concentration can range from about 200 ng/mL to about 2,000 ng/mL,
and in certain embodiments, can range from about 500 ng/mL to about
1,000 ng/mL. A minimum therapeutic concentration and a minimum
adverse concentration will depend on a number of factors such as
the disease being treated, the severity of the disease, the
intended clinical outcome, the condition of the patient being
treated, and so forth. An appropriate interval of dosing may
depend, for example, on the amount of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate in the dosage form, the
composition of the dosage form, the release characteristics of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate from the dosage form, the
disease being treated, the condition of the patient, the potential
adverse effects, and the judgment of the prescribing physician.
Dosage regimens may include repeated administration of the same
dosage form at each interval or different dosage forms at different
intervals. For example, a twice-daily dosage regimen can include
the administration of a first dosage form in the morning, and a
second dosage form in the evening.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can be assayed in vitro and in vivo, for the
desired therapeutic or prophylactic activity, prior to use in
humans. A therapeutically effective dose of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or a therapeutically effective dose of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can provide therapeutic benefit without
causing substantial toxicity and/or adverse side effects. The
toxicity and adverse side effects of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, may be determined using standard
pharmaceutical procedures and may be readily ascertained by the
skilled artisan. The dose ratio between toxic and adverse side
effects and therapeutic effect is the therapeutic index. A dose of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or a dose of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can provide a circulating concentration of
(R)-baclofen that is within a therapeutically effective
concentration with little or no toxicity or adverse side
effects.
Combination Therapy
Dosage forms comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and/or dosage forms comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, may further comprise one or more
pharmaceutically active compounds in addition to crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate. Such compounds may be
provided to treat the same disease or a different disease than the
disease being treated with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, can be used in combination therapy with at
least one other therapeutic agent. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or a pharmaceutical
composition thereof, and the at least one other therapeutic agent
can act additively or synergistically. In certain embodiments,
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, can be used in combination therapy with at
least one other therapeutic agent. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or a pharmaceutical
composition thereof, and the at least one other therapeutic agent
can act additively or synergistically.
In certain embodiments, a pharmaceutical composition comprising
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate can be administered
concurrently with the administration of another therapeutic agent,
which can be part of the same pharmaceutical composition as
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, or the other therapeutic
agent can be in a different pharmaceutical composition. In certain
embodiments, a pharmaceutical composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate can be administered
concurrently with the administration of another therapeutic agent,
which can be part of the same pharmaceutical composition as
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, or the other therapeutic
agent can be in a different pharmaceutical composition. In certain
embodiments, a pharmaceutical composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, and/or a pharmaceutical
composition comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, can be administered prior
to or subsequent to administration of another therapeutic
agent.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered in
combination with an amorphous form of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid; other crystalline form(s) of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid; baclofen; (R)-baclofen; or a
combination of any of the foregoing.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be used in combination
with at least one other therapeutic agent. In certain embodiments,
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient together with another compound for treating movement
disorders such as spasticity, digestive disorders such as
gastro-esophageal reflux disease and emesis, or addictive or abuse
disorders such as nicotine addiction or abuse, alcohol addiction or
abuse, narcotic addiction or abuse, cough, neuropathic pain, or
musculoskeletal pain. In certain embodiments, the at least one
other therapeutic agent may be a different (R)-baclofen prodrug.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and the at least one other
therapeutic agent may act additively or, in certain embodiments,
synergistically.
Accordingly, methods provided by the present disclosure can further
include, in addition to administering crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, administering one or more
therapeutic agents effective for treating the same disease as, or a
different disease than, the disease being treated by crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate. Methods provided by the
present disclosure include administration of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and one or more other
therapeutic agents, provided, however, that the combined
administration does not inhibit the therapeutic efficacy of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate and/or does not produce
adverse combination effects.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered
concurrently with the administration of another therapeutic agent,
which may be part of the same dosage form as, or in a different
dosage form than that comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered prior
to, or subsequent to, administration of another therapeutic agent.
In certain embodiments of combination therapy, the combination
therapy may comprise alternating between: administering crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate; and administering a
composition comprising another therapeutic agent, e.g., to minimize
adverse drug effects associated with a particular drug. When
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is administered
concurrently with another therapeutic agent that may potentially
produce an adverse drug effect including, but not limited to,
toxicity, the other therapeutic agent may advantageously be
administered at a dose that falls below the threshold at which the
adverse drug reaction is elicited.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered with
one or more substances to enhance, modulate and/or control release,
bioavailability, therapeutic efficacy, therapeutic potency,
stability, and the like of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate. For example, to enhance
the therapeutic efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate or the metabolite of such
compounds, (R)-baclofen, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be co-administered
with, or a dosage form comprising crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may comprise, one or more
active agents that act to increase the absorption or diffusion of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate or (R)-baclofen from the
gastrointestinal tract to the systemic circulation, or to inhibit
degradation of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate or (R)-baclofen in the
blood of a patient. In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be co-administered
with an active agent having pharmacological affects that enhance
the therapeutic efficacy of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate.
Additionally, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be used in combination
with other drugs that are themselves known to cause spasticity,
gastroesophageal reflux disease, emesis, cough, substance addiction
and abuse, neuropathic pain and/or musculoskeletal pain as an
adverse effect, thereby preventing or reducing the occurrence of
such adverse effects.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating a movement disorder such as spasticity in
combination with a therapy or another therapeutic agent known or
believed to be effective in treating a movement disorder such as
spasticity. Examples of drugs for treating movement disorders such
as spasticity and which may be administered in conjunction with
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include levodopa; mild
sedatives such as benzodiazepines including alprazolam,
chlordiazepoxide, clonazepam, clorazepate, diazepam, lorazepam, and
oxazepam; muscle relaxants such as baclofen; anticholinergic drugs
such as trihexyphenidyl and diphenhydramine; antipsychotics such as
chlorpromazine, fluphenazine, haloperidol, loxapine, mesoridazine,
molindone, perphenazine, pimozide, thioridazine, thiothixene,
trifluoperazine, aripiprazole, clozapine, olanzapine, quetiapine,
risperidone, and ziprasidone; and antidepressants such as
amitriptyline.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating a gastrointestinal disorder such as
gastro-esophageal reflux disease in combination with a therapy or
another therapeutic agent known or believed to be effective in
treating a gastrointestinal disorder such as gastro-esophageal
reflux disease. Examples of drugs for treating gastrointestinal
disorders such as gastro-esophageal reflux disease and which may be
administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include H.sub.2-receptor
inhibitors such as cimetidine, famotidine, nizatidine, and
ranitidine; proton pump inhibitors such as omeprazole,
lansoprazole, pantoprazole, rabeprazole, and exomeprazole; and
prokinetics such as cisparide, bethanechol, and metoclopramide.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating emesis in combination with a therapy or
another therapeutic agent known or believed to be effective in
treating emesis. Examples of drugs for treating emesis (nausea and
vomiting) and which may be administered in conjunction with
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include benzamines such as
metoclopramide; phenothiazines such as prochlorperazine,
perphenazine, chlorpromazine, promethazine, and thiethylperazine;
butyrophenones such as droperidol and haloperidol; dopamine 2
antagonists such as metoclorpamide; 5-HT.sub.3 antagonists such as
ondansetron, granisetron, dolasetron, palonosetron; NK-1 receptor
antagonists such as aprepitant, corticosteroids such as
dexamethazone; antihistamines such as diphenhydramine and
hydroxyzine; cannabinoids such as dronabinol; and benzodiazepines
such as lorazepam, midazolam, alprazolam, and olanzapine.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating alcohol addiction or abuse in combination with
a therapy or another therapeutic agent known or believed to be
effective in treating alcohol addiction or abuse. Examples of drugs
for treating alcohol addiction or abuse and which may be
administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include disulfuram,
naltrexone, clonidine, methadone, 1-alpha-acetylmethadol,
buprenorphine, and bupropion.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating narcotic addiction or abuse in combination
with a therapy or another therapeutic agent known or believed to be
effective in treating narcotic addiction or abuse. Examples of
drugs for treating narcotic addiction or abuse and which may be
administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include buprenorphine,
tramadol, methadone, and naltrexone.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating nicotine addiction or abuse in combination
with a therapy or another therapeutic agent known or believed to be
effective in treating nicotine addiction or abuse. Examples of
drugs for treating nicotine addiction or abuse and which may be
administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include bupropion,
clonidine, and nicotine.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating cough in combination with a therapy or another
therapeutic agent known or believed to be effective in treating
cough. Examples of drugs for treating cough and which may be
administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include dextromethorphan,
guaifenesin, hydrocodone, benzonatate, diphenhydramine,
pseudoephedrine, acetaminophen, and carbinoxamine.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating neuropathic pain in combination with a therapy
or another therapeutic agent known or believed to be effective in
treating neuropathic pain. Examples of drugs useful for treating
pain and which may be administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include opioid analgesics
such as morphine, codeine, fentanyl, meperidine, methadone,
propoxyphene, levorphanol, hydromorphone, oxycodone, oxymorphone,
tramadol and pentazocine; nonopioid analgesics such as aspirin,
ibuprofen, ketoprofen, naproxen, and acetaminophen; non-steroidal
anti-inflammatory drugs such as aspirin, choline magnesium
trisalicylate, diflunisal, salsalate, celecoxib, rofecoxib,
valdecoxib, diclofenac, etodolac, fenoprofen, flubiprofen,
ibuprofen, indomethacin, ketoprofen, ketorolac, meclofanamate,
mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin,
piroxicam, sulindac, and tometin; antiepileptics such as
gabapentin, pregabalin, carbamazepine, phenyloin, lamotrigine, and
topiramate; antidepressants such as duloxetine, amitriptyline,
venlafaxine, nortryptyline, imipramine, and desipramine; local
anesthetics such as lidocaine, and mexiletine; NMDA receptor
antagonists such as dextropethorphan, memantine, and ketamine;
N-type calcium-channel blockers such as ziconotide; vanilloid
receptor-1 modulators such as capsaicin; cannabinoid receptor
modulators such as sativex; neurokinin receptor antagonists such as
lanepitant; other analgesics such as neurotropin; and other drugs
such as desipramine, clonazepam, divalproex, oxcarbazepine,
divalproex, butorphanol, valdecoxib, vicoprofen, pentazocine,
propoxyhene, fenoprofen, piroxicam, indometnacin, hydroxyzine,
buprenorphine, benzocaine, clonidine, flurbiprofen, meperidine,
lacosamide, desvenlafaxine, and bicifadine.
In certain embodiments, a drug useful for treating neuropathic pain
and which may be administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is chosen from
propoxyphene, meperidine, hydromorphone, hydrocodone, morphine,
codeine, 2-piperidinol-1-alkanol, eliprodil, ifenprodil, rofecoxib,
celecoxib, salicylic acid, diclofenac, piroxicam indomethacin,
ibuprofen, naproxen, gabapentin, carbemazepine, pregabalin,
topiramate, valproic acid, sumatriptan, elitriptan, rizatriptan,
zolmitriptan, naratriptan, flexeril, carisoprodol, robaxisal,
norgesic, dantrium, diazepam, chlordiazepoxide, alprazolam,
lorazepam, acetaminophen, nitrous oxide, halothane, lidocaine,
etidocaine, ropivacaine, chloroprocaine, sarapin, bupivacaine,
capsicin, desipramine, amitriptyline, doxepin, perphenazine,
protriptyline, tranylcypromine, baclofen, clonidine, mexelitine,
diphenhydramine, hydroxyzine, caffeine, prednisone,
methyl-prednisone, decadron, sertraline, paroxetine, fluoxetine,
tramadol, levodopa, dextromethorphan, substance P antagonists, and
botulinum toxin.
In certain embodiments, a drug useful for treating neuropathic pain
and which may be administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is chosen from a nicotine
receptor partial agonist and an analgesic agent as disclosed by Coe
et al., U.S. Patent Application Publication No. 2003/0133951; a
1-aryl-3-azabicyclo[3.1.0]hexane as disclosed by Lippa et al., U.S.
Patent Application Publication No. 2007/00892939; and a
nitro(cyano)vinylpiperazine compound as disclosed by Sun and
Tafesse, U.S. Patent Application Publication No. 2007/0032500.
Non-pharmacological therapies for treating neuropathic pain and
which may be administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include transcutaneous
electrical nerve stimulation, percutaneous electrical nerve
stimulation, and acupuncture.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating fibromyalgia in combination with a therapy or
another therapeutic agent known or believed to be effective in
treating fibromyalgia, or in certain embodiments, a disease,
disorder, or condition associated with fibromyalgia. Drug therapy
for fibromyalgia may be tailored to the severity and frequency of
fibromyalgia episodes. For occasional episodes, acute treatment may
be indicated. For fibromyalgia episodes occurring two or more times
per month, or when attacks greatly impact the patient's daily life,
chronic therapy on an ongoing basis may be appropriate.
Treatments for fibromyalgia that reduce the frequency of episodes
and which may be administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include non-steroidal
anti-inflammatory agents (NSAIDs), adrenergic beta-blockers,
calcium channel blockers, tricyclic antidepressants, selective
serotonin reuptake inhibitors, anticonvulsants, NMDA receptor
antagonists, dopamine agonists, selective 5-HT.sub.3 receptor
antagonists, opioids, muscle relaxants, sedative hypnotics, and
other therapy. Examples of NSAIDs useful for treating fibromyalgia
and which may be administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include aspirin,
ibuprofen, fenoprofen, flurbiprofen, ketoprofen, mefenamic acid,
and naproxen. Examples of adrenergic beta-blockers useful for
treating fibromyalgia and which may be administered in conjunction
with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include acebutolol,
atenolol, imilol, metoprolol, nadolol, pindolol, propranolol, and
timolol. Examples of calcium channel blockers useful for treating
fibromyalgia and which may be administered in conjunction with
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include amlodipine,
diltiazem, dotarizine, felodipine, flunarizine, nicardipine,
nifedipine, nimodipine, nisoldipine, and verapamil. Examples of
tricyclic antidepressants useful for treating fibromyalgia and
which may be administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include amitriptyline,
desipramine, doxepin, imipramine, nortriptyline, cyclobenzaprine,
and protriptyline. Examples of selective serotonin reuptake
inhibitors useful for treating fibromyalgia and which may be
administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include fluoxetine,
methysergide, nefazodone, paroxetine, sertraline, citalopram, and
venlafaxine. Examples of other antidepressants useful for treating
g fibromyalgia and which may be administered in conjunction with
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include bupropion,
nefazodone, norepinephrine, venlafaxine, duloxetine, and trazodone.
Examples of anticonvulsants (antiepileptics) useful for treating
fibromyalgia and which may be administered in conjunction with
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include divalproex sodium,
felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine,
tiagabine, topiramate, valproate, and zonisamide. Examples of NMDA
receptor antagonists useful for treating fibromyalgia and which may
be administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include dextromethorphan,
magnesium, and ketamine. Examples of dopamine agonists useful for
treating fibromyalgia and which may be administered in conjunction
with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include
.alpha.-dihydroergocryptine. Examples of opioids useful for
preventing fibromyalgia and which may be administered in
conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate are tramadol, oxycodone,
and methadone. An example of a muscle relaxant useful for treating
fibromyalgia and which may be administered in conjunction with
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate is cyclobenzaprine.
Examples of therapies useful for treating fibromyalgia and which
may be administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include exercise,
interferon, growth hormone, hormone therapy, diet low in animal fat
and high in fiber, and complementary therapies such as
counseling/psychotherapy, relaxation training, progressive muscle
relaxation, guided imagery, diaphragmatic breathing, biofeedback,
acupuncture, and physical and massage therapy.
Acute fibromyalgia treatments intended to eliminate or reduce the
severity of muscular/skeletal pain and any associated symptoms, and
which may be administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, include serotonin
receptor agonists, such as triptans (5-hydroxytryptophan (5-HTP)
agonists), for example, almotriptan, eletriptan, frovatriptan,
naratriptan, rizatriptan, sumatriptan, and zolmitriptan;
ergotamine-based compounds such as dihydroergotamine and
ergotamine; antiemetics such as metoclopramide and
prochlorperazine; and compounds that provide analgesic effects.
Other examples of drugs useful in treating fibromyalgia and which
may be administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include
acetaminophen-aspirin, caffeine, cyproheptadine, methysergide,
valproic acid; NSAIDs such as diclofenac, flurbiprofen, ketaprofen,
ketorolac, ibuprofen, indomethacin, meclofenamate, and naproxen
sodium; opioids such as codeine, meperidine, and oxycodone; and
glucocorticoids such as dexamethasone, prednisone, and
methylprednisolone.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating musculoskeletal pain in combination with a
therapy or another therapeutic agent known or believed to be
effective in treating musculoskeletal pain. Examples of drugs
useful for treating musculoskeletal pain and which may be
administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include cyclobenzaprine,
dantrolene, methocarbamol, orphenadrine, tizanidrine, metaxalone,
carisoprodol, chlorphenesin, chlorzoxazone, alprazolam, bromazepam,
chlordiazepoxide, clorazepate, diazepam, flunitriazepam, lorazepam,
medazepam, midazolam, oxazepam, prazepam, triazolam, temazepam, and
botulinum toxin. In certain embodiments, any of the drugs useful
for treating neuropathic pain may be coadministered with a prodrug
of a GABA.sub.B agonist for treating musculoskeletal pain.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating low back pain in combination with a therapy or
another therapeutic agent known or believed to be effective in
treating low back pain. Examples of drugs useful for treating low
back pain and which may be administered in conjunction with
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include NSAIDs such as
aspirin, naproxen, and ibuprofen; anticonvulsants; antidepressants
such as amitriptyline and desipramine; and opioids such as codeine,
oxycodone, hydrocodone, and morphine. In certain embodiments, any
of the drugs useful for treating neuropathic pain may be
coadministered with a prodrug of a GABA.sub.B agonist for treating
low back pain. Therapies for low back pain and which may be
administered in conjunction with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include the use of cold
and hot compresses, bed rest, exercise, spinal manipulation,
acupuncture, biofeedback, interventional therapy, traction,
transcutaneous electrical nerve stimulation, ultrasound,
vertebroplasty, kyphoplasty, discectomy, foraminotomy, intradiscal
electrothermal therapy, nucleoplasty, radiofrequency lesioning,
spinal fusion, and spinal laminectomy.
In certain embodiments, crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate may be administered to a
patient for treating low back pain in combination with a therapy or
other therapeutic agent for treating muscle spasms, for example
muscle spasms associated with low back pain, such as muscle
relaxants. Examples of drugs useful as muscle relaxants for
treating muscle spasms and which may be administered in conjunction
with crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and/or crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate include baclofen,
carisoprodol, chlorzoxazone, cyclobenzaprine, diazepam, metaxalone,
methocarbamol, orphenadrine, and tizanidine.
EXAMPLES
The following examples describe in detail the preparation,
properties, and uses of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate and crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate. It will be apparent to
those skilled in the art that many modifications, both to materials
and methods, may be practiced without departing from the scope of
the disclosure.
Example 1
Synthesis of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid; and Separation by Crystallization
To 3 moles of 2-methyl-1-(methylthiocarbonyloxy)propyl isobutyrate
is added N-hydroxysuccinimide and a mixture of dichloromethane and
peracetic acid. The mixture is cooled to 15.degree. C. during the
addition of the mixture of dichloromethane and peracetic acid.
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methylprop-
anoate (3) is extracted from the final solution via cold water
extraction. To the extracted compound (3) a 1:1 mixture of
isopropyl alcohol:hexane is added and the mixture cooled in a
dry-ice bath. Compound (3) crystallizes in this reaction mixture.
The product is collected by filtration and dried to afford 470 g
(53%) of crystalline
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methylprop-
anoate (3).
To a 500 mL, round bottomed flask, is added 21.3 g (R)-baclofen (2)
and 30.1 g compound (3). The two compounds are mixed and a mixture
of 100 mL acetonitrile and 100 mL water is added at room
temperature. The reaction is stirred at room temperature for 4
hours. The reaction mixture is diluted with 500 mL methyl
tert-butyl ether, washed twice with 200 mL water, and washed once
with 100 mL of brine. The methyl tert-butyl ether layer is dried to
afford a mixture of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid.
To 40 g of the mixture of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid is added 800 mL of a 1:1 mixture of
toluene:methylcyclohexane.
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) crystallizes in this reaction
mixture to afford 13 g (65%) of crystalline compound (1). This
crystallization reaction separates
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) from
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid.
Example 2
Separation of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) from
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid by Crystallization
From 3:1 Toluene:Methylcyclohexane
A portion of the mixture of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid produced according to Example 1 is
separated as follows: to 110 g of the mixture of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid is added 3.3 L of a 3:1 mixture of
toluene:methylcyclohexane.
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) crystallizes in this reaction
mixture to afford 88 g (80%) of crystalline compound (1).
A second crystallization is performed as follows: to 20 g of the
mixture of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}--
3-(4-chlorophenyl)butanoic acid (1) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid produced according to Example 1 is
added 400 mL of a 3:1 mixture of toluene:methylcyclohexane.
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) crystallizes in this reaction
mixture to afford 5 g (25%) of crystalline compound (1).
From 1.5:1 Methanol:Water
A portion of the mixture of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid produced according to Example 1 is
separated as follows: 40 g of the mixture of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1) and
(3R)-4-{[(1R)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid is dissolved in a mixture of 150 mL
methanol and 100 mL water. The mixture is heated to 60.degree. C.
and then cooled to room temperature. The heating and cooling
procedure is performed 5 times in succession to yield 6 g (30%) of
crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid (1).
Example 3
Crystallization of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b)
A 2,500 L reaction vessel was charged with 313 L of methyl
tert-butyl ether (MTBE) and 224 L of water, to which was added 100
kg of (R)-baclofen and 134 kg of
1-((2,5-dioxopyrrolidin-1-yl-oxycarbonyloxy)-2-methylpropyl)-2-methylprop-
anoate (3) at 20.degree. C. The charging lock and the reactor walls
were each rinsed with 67 liters of MTBE. The reaction mixture was
heated to 45.degree. C. and stirred for 6.25 hours. The reaction
mixture was then cooled to 20.degree. C., the aqueous phase was
separated and discarded. The organic phase was washed with 224 kg
of 1N hydrochloric acid, followed by two washes with 224 kg of
water each. The product-containing organic phase was filtered
through a charcoal cartridge. The reactor and lines were rinsed
with 137 liters of MTBE, which was also filtered through the
charcoal filter and combined with the previous filtrate. The
combined organic phase was washed once more with 224 kg of
water.
To the filtrate was added 277 L of methylcyclohexane, and 67 L of
MTBE followed by an additional 768 L of methylcyclohexane. The
resulting mixture was heated to 50.degree. C. to dissolve all
solids. The solution was then cooled to 35.degree. C. within one
hour and seeded with 0.25 kg of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}--
3-(4-chlorophenyl)butanoic acid hemihydrate (1b). The resulting
mixture was cooled to 5.degree. C. over a period of ten hours.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) was isolated via
centrifugation, washed with a mixture of 34.4 kilograms of MTBE and
82.6 kg of methylcyclohexane, and dried at a temperature between
45.degree. C. to 75.degree. C. using a vacuum of 25 to 50 mbar.
This resulted in 51.75 kg of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b).
Example 4
Crystallization of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a)
To a 2,500 L reactor was added 51.1 kg of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b) and 104.4 kg of
acetone, at 35.degree. C. To this mixture was added 247.15 kg of
hexane and the mixture was heated to 50.degree. C. and stirred for
10 minutes at this temperature. The temperature was then reduced to
45.degree. C. Thereafter 98 kg of hexane was added, followed by 50
g of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate seed crystals. A further
488.4 kg of hexane was added at 45.degree. C. and the mixture was
cooled to 0.degree. C. within 2.5 hours. Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate was isolated via
centrifugation, washed with a mixture of 168.1 kg of hexane in 23 L
of acetone, and dried at 50.degree. C. using a vacuum of 22-49 mbar
for 15 hours. This resulted in 45.15 kg of
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate.
Example 5
Differential Scanning calorimetry of Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b)
Differential scanning calorimetry was performed using a Perkin
Elmer DSC-7 instrument. DSC on the hemihydrate was carried out in a
gold sample pan sealed in air. Heating occurred at a rate of
20K/min over a temperature range of 0.degree. C.-150.degree. C.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate prepared according to
Example 3 exhibited two distinct melt transitions. The first melt
transition occurred from about 70.degree. C. to about 110.degree.
C., with a peak maximum at about 100.degree. C. and a .DELTA.H of
about 58.3 J/g. The second melt transition occurred from about
110.degree. C. to about 125.degree. C., with a peak maximum at
about 115.degree. C. and a .DELTA.H of about 39.1 J/g.
The lower melting peak near 100.degree. C. corresponds to melting
of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate, while the second melting
peak near 115.degree. C. corresponds to the melting of crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate, which exhibits a depressed
melting point in this case, because of the presence of water
released from the hemihydrate.
Example 6
Thermogravimetric Analysis of Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b)
Thermogravimetric measurements were carried out with a Netzsch
Thermo-Microbalance TG 209 coupled to a Bruker FTIR Spectrometer
Vector 22. The sample was contained in sample pans with a pinhole,
under a N.sub.2 atmosphere. The heating rate was set at 10
K/min.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate prepared according to
Example 3 exhibited a weight loss of about 2.1% up to 170.degree.
C. when heated at a scan rate of 10 K/min. This weight loss, which
occurred predominantly between 80.degree. C. and 130.degree. C., is
attributable to water.
Under the conditions used for TG-FTIR thermal decomposition began
slowly at about 170.degree. C. and increased strongly above
190.degree. C.
Example 7
X-Ray Powder Diffraction Analysis of Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b)
X-ray powder diffraction analyses were performed using a Bruker D8
Advance powder X-ray diffractometer using CuK.alpha. radiation.
2.theta. values are accurate within an error of
.+-.0.1-0.2.degree.. The tube voltage and amperage were set to 35
kV and 45 mA, respectively. The step size was set at 0.017.degree.
(2.theta.), the step time was set at 105.+-.5 sec, and the scanning
range was 2.degree.-50.degree. (2.theta.). The samples were
rotated. Differential radiation was detected by a VANTEC1 detector
having an opening angle of 3.degree. and a total number of active
channels of 360.+-.10. The y-axis (counts or CPS) of the
diffractogram depicted in FIG. 1 does not show the total
intensity(/sec) but rather the value intensity/number of active
detector channels(/sec). Sample holders were silicon single crystal
and sample dimensions were a depth/diameter: 0.1 mm/.about.12
mm.
The X-ray powder diffractogram for crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate prepared according to
Example 3 is shown in FIG. 1. The characteristic scattering angles
for the same crystalline preparation shown in FIG. 1 are presented
in Table 1.
TABLE-US-00001 TABLE 1 XRPD Scattering Angles. .theta.2.theta.
(deg) 4.04.degree. .+-. 0.2.degree. 6.47.degree. .+-. 0.2.degree.
7.97.degree. .+-. 0.2.degree. 9.46.degree. .+-. 0.2.degree.
10.10.degree. .+-. 0.2.degree. 10.87.degree. .+-. 0.2.degree.
12.88.degree. .+-. 0.2.degree. 15.68.degree. .+-. 0.2.degree.
16.72.degree. .+-. 0.2.degree. 18.16.degree. .+-. 0.2.degree.
18.91.degree. .+-. 0.2.degree. 19.33.degree. .+-. 0.2.degree.
19.96.degree. .+-. 0.2.degree. 20.23.degree. .+-. 0.2.degree.
20.62.degree. .+-. 0.2.degree. 21.76.degree. .+-. 0.2.degree.
22.42.degree. .+-. 0.2.degree. 23.55.degree. .+-. 0.2.degree.
24.02.degree. .+-. 0.2.degree. 25.13.degree. .+-. 0.2.degree.
25.61.degree. .+-. 0.2.degree. 26.09.degree. .+-. 0.2.degree.
28.07.degree. .+-. 0.2.degree. 28.53.degree. .+-. 0.2.degree.
29.87.degree. .+-. 0.2.degree. 30.45.degree. .+-. 0.2.degree.
30.74.degree. .+-. 0.2.degree. 31.52.degree. .+-. 0.2.degree.
32.60.degree. .+-. 0.2.degree. 35.94.degree. .+-. 0.2.degree.
36.63.degree. .+-. 0.2.degree.
Example 8
Raman Spectroscopy Analysis of Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate (1b)
FT-Raman spectra were recorded on a Bruker RFS 100 FT-Raman system
with a near infrared Nd:YAG laser operating at 1064 nm and a liquid
nitrogen-cooled germanium detector. A total of 64 scans with a
resolution of 2 cm.sup.-1 were accumulated in the range from 3500
to 50 cm.sup.-1. In general, 100 mW laser power was used.
Dispersive Raman spectra were taken on a Renishaw RM 1000 System
using a 20.times. long working distance objective lens in
conjunction with a diode laser operating at 785 nm. The
measurements were carried out over the range 2000 cm.sup.-1 to 100
cm.sup.-1.
The Raman spectrum for crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid hemihydrate prepared according to
Example 3 is shown in FIG. 2.
The most prominent bands were found at 1744 cm.sup.-1, 1600
cm.sup.-1, 1453 cm.sup.-1, 1290 cm.sup.-1, 1238 cm.sup.-1, 1201
cm.sup.-1, 954 cm.sup.-1, 872 cm.sup.-1, 779 cm.sup.-1, 635
cm.sup.-1, 362 cm.sup.-1, 315 cm.sup.-1, 110 cm.sup.-1, and 84
cm.sup.-1. The band at 110 cm.sup.-1 was the strongest Raman
spectrum band displayed.
Example 9
Differential Scanning Calorimetry of Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a)
Differential scanning calorimetry was performed using a Perkin
Elmer DSC-7 instrument. DSC on the hemihydrate was carried out in a
gold sample pan sealed under nitrogen. Heating occurred at a rate
of 20K/min over a temperature range of 0.degree. C.-150.degree.
C.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate prepared according to the
methods of the present disclosure exhibited a single melt
transition from about 120.degree. C. to about 145.degree. C., with
a peak maximum at about 131.degree. C. and a .DELTA.H of about 92.6
J/g.
Example 10
Thermogravimetric Analysis of Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a)
Thermogravimetric measurements were carried out with a Netzsch
Thermo-Microbalance TG 209 coupled to a Bruker FTIR Spectrometer
Vector 22. The sample was contained in sample pans with a pinhole,
under a N.sub.2 atmosphere. The heating rate was set at 10
K/min.
Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate prepared according to the
methods of the present disclosure showed very little weight loss up
to 180.degree. C. when heated at a scan rate of 10 K/min.
Under the conditions used for TG-FTIR, thermal decomposition began
slowly at about 170.degree. C. and increased strongly above
190.degree. C.
Example 11
X-Ray Powder Diffraction Analysis of Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a)
X-ray powder diffraction analyses were performed using a Bruker D8
Advance powder X-ray diffractometer using CuK.alpha. radiation.
2.theta. values are accurate within an error of
.+-.0.1-0.2.degree.. The tube voltage and amperage were set to 35
kV and 45 mA, respectively. The step size was set at 0.017.degree.
(2.theta.), the step time was set at 105.+-.5 sec, and the scanning
range was 2.degree.-50.degree. (2.theta.). The samples were
rotated. Differential radiation was detected by a VANTEC1 detector
having an opening angle of 3.degree. and a total number of active
channels of 360.+-.10. The y-axis (counts or CPS) of the
diffractogram depicted in FIG. 3 does not show the total
intensity(/sec) but rather the value intensity/number of active
detector channels(/sec). Sample holders were silicon single crystal
and sample dimensions were a depth/diameter: 0.1 mm/.about.12
mm.
The X-ray powder diffractogram for crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate prepared according to the
methods of the present disclosure is shown in FIG. 3. The
characteristic scattering angles for the same crystalline
preparation shown in FIG. 3 are presented in Table 2.
TABLE-US-00002 TABLE 2 XRPD Scattering Angles. .theta.2.theta.
(deg) 4.33.degree. .+-. 0.2.degree. 4.76.degree. .+-. 0.2.degree.
5.83.degree. .+-. 0.2.degree. 6.93.degree. .+-. 0.2.degree.
9.07.degree. .+-. 0.2.degree. 9.46.degree. .+-. 0.2.degree.
10.54.degree. .+-. 0.2.degree. 11.06.degree. .+-. 0.2.degree.
11.61.degree. .+-. 0.2.degree. 12.94.degree. .+-. 0.2.degree.
15.25.degree. .+-. 0.2.degree. 16.55.degree. .+-. 0.2.degree.
17.46.degree. .+-. 0.2.degree. 17.84.degree. .+-. 0.2.degree.
18.01.degree. .+-. 0.2.degree. 18.41.degree. .+-. 0.2.degree.
18.69.degree. .+-. 0.2.degree. 18.93.degree. .+-. 0.2.degree.
19.36.degree. .+-. 0.2.degree. 20.01.degree. .+-. 0.2.degree.
20.46.degree. .+-. 0.2.degree. 21.26.degree. .+-. 0.2.degree.
21.75.degree. .+-. 0.2.degree. 22.19.degree. .+-. 0.2.degree.
22.56.degree. .+-. 0.2.degree. 23.35.degree. .+-. 0.2.degree.
23.85.degree. .+-. 0.2.degree. 24.84.degree. .+-. 0.2.degree.
25.96.degree. .+-. 0.2.degree. 26.78.degree. .+-. 0.2.degree.
27.29.degree. .+-. 0.2.degree. 28.69.degree. .+-. 0.2.degree.
29.39.degree. .+-. 0.2.degree. 31.22.degree. .+-. 0.2.degree.
32.35.degree. .+-. 0.2.degree. 33.47.degree. .+-. 0.2.degree.
34.62.degree. .+-. 0.2.degree. 36.08.degree. .+-. 0.2.degree.
Example 12
Raman Spectroscopy Analysis of Crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate (1a)
FT-Raman spectra were recorded on a Bruker RFS 100 FT-Raman system
with a near infrared Nd:YAG laser operating at 1064 nm and a liquid
nitrogen-cooled germanium detector. A total of 64 scans with a
resolution of 2 cm.sup.-1 were accumulated in the range from 3500
to 50 cm.sup.-1. In general, 100 mW laser power was used.
Dispersive Raman spectra were taken on a Renishaw RM 1000 System
using a 20.times. long working distance objective lens in
conjunction with a diode laser operating at 785 nm. The
measurements were carried out over the range 2000 cm.sup.-1 to 100
cm.sup.-1.
The Raman spectrum for crystalline
(3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(-
4-chlorophenyl)butanoic acid anhydrate prepared according to the
methods of the present disclosure is shown in FIG. 4.
The most prominent bands were found at 1747 cm.sup.-1, 1599
cm.sup.-1, 1447 cm.sup.-1, 1412 cm.sup.-1, 1335 cm.sup.-1, 1203
cm.sup.-1, 1092 cm.sup.-1, 954 cm.sup.-1, 868 cm.sup.-1, 798
cm.sup.-1, 637 cm.sup.-1, 401 cm.sup.-1, 348 cm.sup.-1, 317
cm.sup.-1, 244 cm.sup.-1, 119 cm.sup.-1, and 85 cm.sup.-1. The band
at 119 cm.sup.-1 was the strongest Raman spectrum band
displayed.
Finally, it should be noted that there are alternative ways of
implementing the embodiments disclosed herein. Accordingly, the
present embodiments are to be considered as illustrative and not
restrictive. Furthermore, the claims are not to be limited to the
details given herein, and are entitled their full scope and
equivalents thereof.
* * * * *